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Abstract
Herc5 is a potent HIV-1 restriction factor able to restrict HIV-1 by two mechanisms: 1) 
conjugation of ISG15 to gag polyprotein via E3 ligase activity, and 2) restricting the 
production of HIV-1 proteins by an unknown mechanism that is independent of its E3 
ligase function. Herc5 mutations of the RCCl-like domain (RLD) and Spacer domains 
were generated to dissect this mechanism. Based on HIV-1 release assays, the RLD is 
important for preventing the production of viral proteins. Herc5 transfected cells show 
defects in cell cycle progression at the G2/M phase as well as abnormal nuclear 
morphology. C994A and ASpacer constructs did not impact these phenotypes. However, 
ARLD Herc5 constructs had normal cell cycle and nuclear morphology. Based on the 
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Chapter 1: Introduction
1.1 Overview of Ubiquitination
Ubiquitination of proteins has a large role in maintaining homeostasis in the host 
by altering a wide variety of cellular processes such as, apoptosis, cell cycle, DNA 
transcription, and antiviral immune responses. The conjugation of ubiquitin to target 
proteins requires three enzymatic reactions from three classes of enzymes, the E l, E2, 
and E3, in sequential steps [1]. The initiation of this process involves the activation of 
ubiquitin by E l through an ATP dependent mechanism, forming a ubiquitin-adenylate 
intermediate and results in binding to a cysteine residue of the El via a thioester bond. 
This activated ubiquitin is then passed to a cysteine residue on the E2 enzyme via a trans- 
thiolation reaction. The E2 then passes ubiquitin to an E3 ligase enzyme which 
conjugates the c-terminus of ubiquitin to a lysine residue on a target protein. The process 
of ubiquitination can lead to formations of poly-ubiquitin chains on target substrates. The 
length and binding site of the poly-ubiquitin chain on the substrate can have a variety of 
affects including alternative protein trafficking, degradation, or signalling events to occur. 
The variety of ubiquitin linkages derives from the diversity of E l, E2, and E3 enzymes 
that are able to conjugate ubiquitin to targets, E3s being the most diverse class amongst 
ubiquitinating enzymes with over a hundred known E3 ligases [2,3],
There are two main classes of E3 ligases: RING (Really Interesting New Gene) 
domain E3 ligases and HECT (Homologous to the E6-AP Carboxyl terminus) domain. 
These two classes differ in the way they interact with ubiquitin and their target substrate 
[3]. RING E3 ligases act as scaffold proteins, binding both E2 and substrate protein,
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which brings them in close proximity to one another and facilitates the direct transfer of 
ubiquitin from the E2 to the target substrate. HECT (Homologous to the E6-AP (ube3A) 
Carboxyl Terminus) domain E3 ligases however, form an E3-ubiquitin thiol-ester 
conjugate intermediate. In this instance, ubiquitin is transferred from the E2 enzyme to 
the HECT E3 ligase which then catalytically conjugates ubiquitin to the amine group of a 
lysine residue on a bound substrate, the specifics of which are unknown [3] 
(Supplementary Figure 1). For substrate proteins to be capable of accepting ubiquitin 
each must contain either a ubiquitin associated domain, ubiquitin interacting motif, 
ubiquitin E2 variant or CUE-1 homologous sequence. Each of these ubiquitin binding 
domains is commonly affiliated with specific protein and cellular activities such as 
ubiquitin linkage patterns, DNA repair, degradation, and signalling which may in part be 
responsible for the diversity of ubiquitin functions [4-6].
1.2 HECT E3 ligases
HECT domain containing proteins were first discovered in E6 associated protein 
(E6-AP), a cellular factor which associates with the Human Papilloma Viruses 16 and 18 
(HPV16 and HPV18). This HECT domain containing protein targets p53 for 
ubiquitination and proteasomal degradation which enhances viral replication for HPV16 
and HPV18 [7,8]. Sequence analysis of the C-terminus of E6-AP shows 28 proteins 
containing similar C-terminal sequences which formed a new class of proteins 
subsequently designated HECT domain containing proteins [9]. C-terminal HECT 
domains perform the catalytic function of conjugating ubiquitin on to its target substrates, 
while the N-terminus of most HECT containing proteins are reserved for recognizing and 
maintaining substrate specificity [10-12]. These N-terminal regions of HECT containing
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proteins are subcategorized into three different groups: 1) RLD (RCCl-like domain) 
containing HECT proteins, 2) WW domain containing HECT proteins called 
NEDD4/NEDD4-like E3s, and 3) Singular HECT proteins which neither contain an RLD 
or a WW domain [13-15],
The precise mechanism by which the HECT domain conjugates ubiquitin to a 
substrate remains unclear. However, all HECT E3 ligases have at least 4 biochemical 
activities: i) they bind to specific E2s ii) they form ubiquitin-thioester intermediates on 
their active-site cysteine when ubiquitin is transferred from the E2 iii) it conjugates 
ubiquitin on lysine residues of target proteins by catalyzing the formation of an isopeptide 
bond iv) it conjugates additional ubiquitin molecules on the lysine residues of the already 
conjugated ubiquitin forming a chain [16], Crystal structure analysis of the HECT 
domain of E6-AP shows that the HECT is a bi-lobed structure made up of the N-lobe and 
the C-lobe which are connected by a flexible hinge made up of 3 amino acids. This 
structure is maintained through most HECT domain containing proteins and is important 
for the catalytic activity of the domain as well as its interaction with a specific E2. The 
N-lobe of the E6-AP HECT domain forms a V shaped groove which is responsible for 
interaction with its E2, UbcH7, while the C-lobe contains the active-site cysteine residue 
responsible for accepting the ubiquitin transfer [16]. Once the UbcH7 is bound to the 
groove of the N-lobe, the active-site cysteine residues on both UbcH7 and E6-AP are 
only 41A apart and have an open line of sight between them for the easy transfer of 
ubiquitin. Interestingly it has been proposed that the N-lobe binding of the E2 is stable 
and is maintained throughout the entire E1-E2-E3 enzymatic cascade facilitating the 
efficient transfer of ubiquitin.
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This bi-lobed HECT domain structure is clearly an important feature for the 
proper functioning of HECT proteins such as WWP1. Two models have been proposed 
to describe how the HECT domain structure relates to the mechanism by which WWP1 
HECT E3 acts to ubiquitinate target substrates. 1) the C-lobe rotates along the hinge 
region and acquires ubiquitin molecules from the bound E2 on the N-lobe via a thioester 
bond and tethers to the active- site cysteine residue which subsequently modifies the 
target protein through a isopeptide bond. This continuously occurs until the growing 
ubiquitin chain interferes with the flexibility of the hinge region and consequently 
interrupts further ubiquitination. 2) Ubiquitin chain elongation occurs before the 
conjugation of the poly-ubiquitin chain on the target protein. Here the transfer of 
ubiquitin from the E2 to the E3 occurs in the same fashion as the first model but differs in 
that it proposes that the ubiquitin chain forms on the active-cysteine residue on the C-lobe 
of the HECT domain. The C-lobe continuously rotates along the hinge region to bring 
the C-lobe lysine residues of attached ubiquitin within close proximity of the thioester 
bond between the E2-ubiquitin conjugate on the N-lobe. This consequently forms the 
ubiquitin chain and stops when the ubiquitin chain interferes with the flexibility of the 
hinge region. This poly-ubiquitin chain is collectively transferred to the target protein in 
one step [17].
It has been noted repeatedly in literature that different HECT domains favour 
certain conformations of ubiquitin chains. For example, E6-AP favours K48 linkages of 
ubiquitin (linkages of ubiquitin at the 48th residue-lysine) which subsequently leads to 
proteasomal degradation of these protein targets [18,19]. In contrast, the HECT proteins 
NEDD4 and Itch have been shown to favour K63 linkages of ubiquitin (chains of
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ubiquitin linked at the lysine residue at the 63rd amino acid) for proteasome-independent 
processes such as DNA repair, endocytosis, and NF-kB activation [20,21]. Mutational 
analysis suggests that the C-lobe of HECT domains carries the specificity for these 
various ubiquitin linkages. Chimeras in which the C-lobe and linker of the HECT 
domain of the protein Rsp5 (typically promotes K63 linked ubiquitin chains) are replaced 
with the C-lobe and linker of E6-AP (favouring K48 linked ubiquitin) show almost 
exclusive production of K48 linked ubiquitin chains on target proteins [22]. When only 
the C-terminal portion of the C-lobe of Rsp5 was replaced with the C-terminal portion of 
the C-lobe of E6-AP, the same K48 linked ubiquitin chains were formed again almost 
exclusively. This data which strongly suggests this C-terminal region (60 amino acids) of 
the C-lobes of Rsp5 is responsible for the patterns of ubiquitinylation [22] however it is 
unclear whether this parallels all HECT domains.
The regulation of the function of E3 ligases especially HECT E3s is 
physiologically crucial in maintaining human health. For example, disregulation of the 
E6-AP HECT domain containing protein in which there is inappropriate activation of the 
E3 ligase has been linked to the development of cervical cancer. The highest risk factor 
for the development of cervical cancer is HPV. One of the most effective modes of 
restricting HPV replication is through the tumour suppressor protein p53 [10]. For 
efficient replication of HPV the E6 protein, encoded in the viral genome, hijacks the 
cellular protein E6-AP which together promote the recognition, binding, and 
ubiquitination of p53 leading to its proteasomal degradation and enhancing viral 
replication [23].
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The onset of Liddle’s Syndrome is also due to disregulated ubiquitination. This 
disease is characterized by high blood pressure and low levels of aldosterone and renin 
due to an excessive reabsorption of sodium from the nephron in the kidneys. The 
disregulation in reabsorption is due to a high number of epithelial sodium channels on the 
apical side (facing the urinary tract) causing an increase influx of sodium back into the 
body. These channels are made up of three homologous transmembrane subunits, a, p, 
and □. The C-terminus of each of these subunits has a PY motif which allows for the 
binding of the WW domains of NEDD4-1 and NEDD4-2 HECT domain containing 
proteins and ubiquitination of the N-termini of the subunits leading to the sequestration of 
the channel and degradation. In Liddle’s syndrome patients, the gene encoding either the 
P or □ subunit is mutated causing a deformed or deleted PY motif which subsequently 
eliminates NEDD4-1 and NEDD4-2 binding and leads to an accumulation of epithelial 
sodium channels at the membrane [10,24,25]. This excessive sodium retention causes 
constipation, fatigue, heart palpitations, and chronic hypertension.
1.3 Ubiquitin-like proteins/ modifiers
Similarly to ubiquitin, other posttranslational modifications exist which alter 
proteins using the same E1-E2-E3 enzyme cascade reaction. This constitutes a growing 
family of proteins called ubiquitin-like modifiers (Ubls). ISG15 was the first and least 
characterized protein of this family of proteins. These proteins do not share much 
sequence homology with ubiquitin however some show a great amount of structural 
similarity. Ubls also are functionally distinct from ubiquitin. Although they may be 
involved in protein degradation, they have a diverse range of regulatory functions 
including, protein stability, altering protein affinity, or changing localization.
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1.31 SUMO (Small Ubiauitin-like Modifier)
The process of SUMOylation (conjugation of sumo on proteins) has a variety of 
functions in the cell including cell cycle regulation, transcription, localization, 
localization, degradation, and chromosomal organization [26]. Before conjugation, a pro­
form of SUMO is cleaved at the C-terminus by SUMO specific proteases (SENPs) to 
create activated SUMO. From this stage, the heterodimer Uba2/Aosl binds SUMO in an 
ATP dependent manner, acting as its El enzyme. The E l dimer then passes SUMO to 
its E2 enzyme, Ubc9 - the only known E2 for SUMO, and is attached to an active-site 
cysteine residue (similarly to ubiquitin). Ubc9 then interacts with one of a number of 
different E3 ligases found for SUMO.
Two-thirds of SUMOylation target proteins contain at least one yKxE/D motif 
where \y represents a large hydrophobic residue such as valanine, leucine, or methionine, 
and x is any residue. It is possible that the pool of SUMOylatable proteins is much larger 
than previously thought seeing as one-third to half of human proteins contain this motif 
[27,28]. Currently most SUMOylatable proteins are found in the nucleus. Some of these 
proteins are involved in repressing DNA transcription by binding to transcriptional 
inhibitors/co-repressors of transcription and enhancing their function or by binding to 
transcription factors and co-activators and inhibiting their activity [29,30,40].
Some nuclear SUMOylated proteins are involved in RNA editing by co-localizing 
with the RNA editing protein, ADAR1. ADAR1 functions to destabilize dsRNA through 
the conversion of adenosine into inosine. Since inosine functions as a guanosine during 
translation, the conversion of adenosine into inosine leads to amino acid changes and 
results in alterations of protein function, and alternative RNA splicing [31,32].
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SUMOylation of proteins has also been shown to counteract their ubiquitination 
and subsequent degradation. The E3 ubiquitin ligase and tumor suppressor protein 
vonHippel-Lindau (VHL) has been shown to be regulated by both SUMOylation and 
ubiquitination. One of VHLs most researched targets is HIFla, a transcription factor 
leading to the upregulation of cyclinDl, the progression of cell cycle, and related to 
tumorigenesis [38]. Ubiquitination of H IFla by VHL has been shown to destabilize the 
protein and lead to its degradation and protection against tumorigenesis [38, 39].
However, mutations in VHL or hypermethylation in its gene can lead to the development 
of renal cell carcinomas and sporadic hemangioblastomas of the CNS due to increased 
levels of H IFla [39]. The lysine residues at position 171 and 196 of VHL are targeted by 
both ubiquitin and SUMO and are the main regulators of the protein; where 
ubiquitination leads to its degradation and SUMOylation causing increased stability [38]. 
Moreover, SUMOylation of VHL is able to out-compete ubiquitin for binding at these 
lysine residues and stabilize VHL expression. This may in part be due to the alternative 
trafficking patterns of ubiquitinated versus SUMOylated VHL. It is possible that the 
ubiquitination of VHL leads to proteasomal degradation in the cytoplasm as opposed to 
SUMOylated VHL which is stabilized and maintains transcriptional regulation within the 
nucleus [38].
Upon recognition of ssRNA viruses (like Human Immunodeficiency Virus [HIV]), 
RIG-I activates itself by unfolding from an autoinhibitory conformation, a process 
initiated by ubiquitination of the lysine residue at position 172. After which, RIG-I 
induces a cascade of reactions that lead to the transcription and production of interferon 
(for more information on interferon, see section 1.5). It has been suggested that
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SUMOylation of RIG-I has a positive regulatory affect on the activity of the protein. 
Particularly, SUMOylation of RIG-I increases its ubiquitination and enhances activation 
and interaction with the downstream adaptor protein, cardif which also enhances 
expression interferon [45].
Many viruses however have their own means of circumventing these cellular 
defences or even utilizing SUMOylation for their own benefit. For example, the non- 
structural protein 1 (NS1) of Influenza A is essential for efficient replication of vims in 
human cells. Particularly, NS1 antagonizes the interferon response [41]. It does so by 
binding to viral ssRNA and sequestering it so that ssRNA binding proteins like RIG-I are 
less readably activated by viral RNA and therefore impedes interferon mRNA production
[42] , NS1 is also able to impede the translation of interferon mRNA through the 
formation of an inhibitory complex with specific nuclear mRNA export proteins as well 
as proteins which form the nuclear pore thus trapping mRNA in the nucleus and 
preventing access to cytoplasmic ribosomes. Therefore the production of interferon is 
disrupted at two stages by the NS1 protein, at the transcription level as well as translation
[43] . It has recently been shown that the C-terminus of NS1 is SUMOylated at lysine 
residues K219 and K221 and contributes to protein stability. It has also been shown that 
SUMOylation of NS1 also marginally increases the replication rate of H5N1 and viral 
titres [44],
1.32 NEDD8 (Neural precursor cell expressed, developmentallv down-reeulated
81
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Of all ubiquitin like proteins (Ubls), NEDD8 shows the highest degree of 
sequence similarity to ubiquitin (-60%). Like the E l for SUMO, the NEDD8 El is a 
heterodimer composed of the proteins, APPBP1 and Uba3. Like ubiquitin and SUMO, 
NEDD8 is transferred via thioester bonds to the E2, Ubcl2, and the E3 ligase (of which 
there are no specific NEDD8 only ligases) [46]. The most well characterized NEDD8 
target is the cullin family of proteins. Cullins are scaffold proteins for the SCF 
(Skpl/cullin/Fbox) complex, a multi-subunit ubiquitin E3 family. The SCF family of E3 
ubiquitin ligases are predominantly involved in the regulation of cell cycle progression, 
proteasomal degradation, and transcriptional regulation. The Rbx E3 ligase is a dual 
conjugating ligase as it also acts to conjugate NEDD8 to cullins. NEDD8 modification of 
cullin by Rbx subsequently enhances SCF mediated ubiquitination as well as increased 
proteasomal degradation. NEDD8 modification of cullin aids in the recruitment of the E2 
enzyme, ubc4, to the SCF complex and accelerates their association by increasing Ubc4 
affinity for SCF [47,48,49],
Since many SCF E3 ligases are essential for cell cycle progression it is no wonder 
that NEDDylation is also a required for cell cycle. In mice lacking Uba3, one of the 
proteins of the NEDD8 El enzyme, mitotic and endoreduplicative cell cycle events are 
arrested [51]. Endoreduplication involves the replication of the nuclear genome in the 
absence of cell cycle progression and leads to a build up of nuclear gene content. The 
significance of this phenomenon is currently speculative, however some suggest that in 
embryogenesis endoreduplication is responsible and necessary for a mass production of 
proteins that are required for the high metabolic demands of the developing fetus [50]. It 
has also been shown to be involved in DNA damage resistance and cell differentiation.
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NEDDylation of cullin 1 and cullin3 of different SCF E3 ligases are required for the 
transition of mitotic cell cycle to endoreduplicative cell cycle and the continuance of 
endoreduplicative cell growth [51]. Fetal mice lacking NEDDylation capabilities died in 
utero at the preimplantation stage of embryogenesis due to a number of complications 
relating to DNA damage and even carcinogenesis [51].
Interestingly certain viruses have evolved to incorporate NEDD8 sequences into 
their genome. Bovine Viral Diarrhea Virus (BVDV) is a positive sense (+) ssRNA virus 
made up of one open reading frame which codes for a large polyprotein that is cleaved to 
form 14 different structural and non-structural viral proteins. The insertion of the 
NEDD8 sequence into the p821 strain of BVDV occurs between the third and fourth 
codons of the NS3 gene and subsequently leads to a different N-terminal amino acid 
sequence. It has been shown that this insertion of NEDD8 into the NS3 sequence acts as 
a processing signal to yield NS3, an RNA helicase necessary for the synthesis of the 
negative sense RNA strand and infectious virus particles[52,53].
1.33 ISG15 (Interferon Stimulated Gene 15)
(Refer to section 1.52)
1.4 HIV replication
1.41 Virus structure
HIV is an enveloped virus with two (+) ssRNA genomes that belong to the virus family 
Retroviridae or retroviruses. This class of virus is unique in that their ssRNA genomes 
are converted into dsDNA and are then integrated into the host genome where it becomes
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a provirus and replicates itself in parallel with the host cell using host cell machinery 
[140]. HIV encodes for 9 open reading frames (ORFs). The three largest are the 
polyproteins Gag, Pol, and Env which are later proteolytically processed into individual 
proteins that are common to every member of the retrovirus family. The gag polyprotein 
is cleaved into 4 different proteins, the matrix, the capsid, the nucleocapsid, and P6 which 
eventually make up the structural components of the virus [68], The Pol polyprotein is 
cleaved into the protease, reverse transcriptase, and integrase which provide enzymatic 
functions which are necessary for the HIV lifecycle and are packaged within the mature 
vims [69], The Env polyprotein encodes for cell surface receptor gpl20 as well as 
transmembrane protein gp41. These two proteins make up the outer envelope proteins of 
HIV [67], HIV also encodes for 6 accessory proteins, 3 of which (Viral Protein R [vpr], 
Virion Infectivity Factor [vif], and Negative Regulatory Factor [nef]) are packaged with 
the vims [66], Trans-activator of Transcription (Tat) and Regulator of Virion Expression 
(rev) are necessary for gene regulatory functions and Viral Protein U (vpu) assists in 
vims assembly; these proteins make up the remaining accessory proteins. In total, HIV is 
made up of 15 proteins and two copies of (+) ssRNA genome (Fig. i).
1.42 HIV life cycle
Viral entry and uncoating
HIV infection occurs when the envelope protein gpl20 binds to the CD4 receptor found 
on CD4+ T cells. Mucosal sites, such as the genital mucosa, have a large CD4+ T cell 
population and act as a major site for viral infection. After gpl20 binds to the CD4 
receptor, a conformational change occurs to allow for additional binding to the cellular 
co-receptor CXCR4 [65]. HIV strains which target CD4 T cells predominately are
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termed T cell line tropic. Some HIV strains have shown different cell tropism and infect 
macrophages predominantly. These macrophage tropic viruses also bind to CD4 but use 
the co-receptor CCR5 as a co-receptor for entry [73]. Once adherence to the cell is 
established, gp41 on the HIV envelope is exposed and also reaffirms adherence on the 
cellular membrane. Gp41 also aids in bringing HIV and the cell in close contact to 
promote the fusion of the viral and cellular envelopes [70]. This facilitates the release of 
the viral core, or capsid, into the cytoplasm along with a number of packaged viral 
proteins which are necessary for subsequent steps of viral replication (nucleocapsid, 
reverse transcriptase, integrase, and vpr). Within one hour of envelope fusion, the capsid 
is degraded or “uncoated” and the ssRNA genome is released into the cytoplasm and is 
then reverse transcribed by the viral protein, reverse transcriptase [71,72], Although the 
mechanism of capsid uncoating is not well characterized, it has been thought that the 
degradation of the capsid is mediated by phosphorylation events in the cytoplasm [74,75]. 
It has been hypothesized that the catalytic domain of cellular cAMP, the C-PKA subunit, 
can target capsid proteins and phosphorylate them to destabilize the structure and release 
of HIV genomic RNA [74],
Reverse transcription
After the release of the viral genome and viral enzymes into the cytoplasm, the 
reverse transcription complex is formed. This complex is made up of the viral reverse 
transcriptase enzyme (RT), genomic RNA or viral RNA (vRNA) (flanked on each end by 
short direct repeats known as, R), and a cellular transfer RNA (tRNA)- tRNA3 Lys [76]. 
This complex is required for the conversion of vRNA into DNA so that it may be 
incorporated into the host genome. tRNA3 Lys acts as a primer and binds to vRNA [76].
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This initiates the binding, initiation, and elongation by reverse transcriptase reading the 
template in a 3’ to 5’ direction and generating the DNA in a 5’ to 3’ direction. This leads 
to generation of a negative sense (-) DNA copy hybridized to vRNA [76]. In addition to 
its polymerase activity, RT also contains RNase H which selectively degrades RNA when 
it is part of an RNA-DNA hybrid. This degrades the parental RNA strand that is 
complexed with the (-) DNA and exposes the ssDNA with the exception of a small 
fragment of vRNA which is still bound to the (-) DNA. This small fraction of vRNA acts 
as a primer for the synthesis of the (+) DNA strand. Synthesis of the second strand is in 
the 5’ to 3’ and subsequently creates cDNA from the vRNA genome [76].
Nuclear Entry and Integration
Effective replication of HIV requires the active transport of generated cDNA from 
the cytoplasm into the nucleus and integration into the host genome without the 
breakdown of the nuclear envelope. Transport of HIV across the nuclear membrane 
requires three proteins, matrix, integrase (IN), and vpr, which associate with viral cDNA 
and form the pre-integration complex. Both IN and MA proteins contain nuclear 
localization signals which are important for the direction of the pre-integration complex 
into the nucleus. It is thought that the key regulator of the pre-integration complex is vpr 
which binds to the nuclear transport molecule importin a. This interaction has been 
shown to increase the affinity of importin a  for the nuclear localization signals of both the 
matrix and IN. This leads to the heterodimerization of importin a with importin P and 
allows for the docking and transport of the entire pre-integration complex through the 
nuclear pore and into the nucleus [80].
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Integration of viral cDNA into the host genome requires the viral enzyme IN. IN 
has two major catalytic functions, endonucleic cleavage of 3’OH groups of viral DNA 
and strand transfer reaction allowing for the transfer and incorporation of viral DNA into 
host DNA [81-86]. At each end of the viral DNA strand, an IN dimer binds and cleaves 
3’OH groups, also known as 3’ processing, resulting in the removal of a dinucleotide 
from each end of the viral DNA [87], The two IN dimers then come together to form an 
IN tetramer and also bring the two ends of viral DNA together [88], As IN performs its 
catalytic activity, IN simultaneously binds the viral DNA as well as 26 base pairs (bp) of 
target host DNA. The resulting cleaved viral DNA is then integrated into the host 
genome with 5bp between the two points of insertion in a process called strand transfer 
[87-92].
Transcription
Transcriptional initiation of HIV replication requires the binding of a number of 
cellular transcription factors and enzymes to the promoter region of the HIV genome 
located at the U3 region of the long terminal repeat (LTR). The HIV promoter contains 
two NF-kB and three Spl binding sites for their respective transcription factors as well as 
an initiator site called, start-site region [103,104]. These sites are located upstream of the 
RNA polymerase II (RNAPII) TATA box region also located on the HIV promoter. The 
TATA box is recognized by the TATA binding protein which also binds 8-12 additional 
TATA associated factors [105,106]. Once all transcription factors and associated TATA 
associated factors are bound, RNAPII binds to TATA binding protein and is able to 
initiate transcription. However, only low levels of short vRNA transcripts are produced 
[107-109],
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Highly efficient transcription of the HIV provirus requires the association of the 
viral protein tat to the promoter. This is only possible through the expression of TAR 
RNA. All HIV RNA transcripts express a TAR element (Trans-activation Response 
Element), a stem loop secondary structure found at the 5’ end of vRNA, and serves as a 
binding site for tat [93,94], The low levels of short RNA transcripts generated initially 
act as an attractant for tat binding. Tat-TAR interactions are stabilized by the recruitment 
of cyclin T l, leading to higher affinity binding of tat-TAR [95]. The cellular protein 
Cdk9 also binds to this complex and together with cyclin T l constitutes the positive 
transcription elongation factor b (p-TEFb) [96]. P-TEFb is hyperphosphorylates the 
carboxyl terminal domain of RNA polymerasell and enhances its function which 
generates elongated RNA transcripts [96-99]. Acetylation of tat also helps to generate 
elongated transcripts by binding the PCAF protein which causes the dissociation of tat-p- 
TEFb and PCAF from TAR and RNAPII [100-102],
Nuclear Export o f Viral RNA and Translation
Full length RNA transcripts function both as genomic RNA as well as mRNA for 
the expression of gag and pol genes. However, expression of genes downstream from 
gag and pol require extensive splicing of the primary transcript. With the exception of a 
few viral mRNA (nef, tat, and Rev) most viral transcripts require the viral protein Rev to 
be shuttled out of the nucleus [141,142], After its translation in the cytoplasm, Rev 
relocalizes to the nucleus through a nuclear localization signal, an arginine rich motif on 
Rev which binds the cellular nuclear import factor Importin P [143]. In the nucleus, 
multimers of Rev bind to a stem loop structure located in the Env gene called the Rev
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response element (RRE) through the same arginine rich motif and masks the nuclear 
localization signal [144,145].
The export of Rev-RRE complexes require a nuclear export signal which is a 
leucine rich sequence found on the C-terminus of Rev [146]. This allows Rev-RRE to 
hijack a cellular pathway for RNA export [146]. The cellular protein, Crml, binds Rev- 
RRE and localizes to the nuclear pore complex and interacts with a number of nuclear 
proteins including Ran, a GTPase that is involved in RNA export to the cytoplasm [147- 
149, 138]. RNA export by Ran requires an energy gradient created by an asymmetric 
distribution of Ran-GTP and Ran-GDP across the nuclear membrane (high levels of 
nuclear Ran-GTP in the nucleus, low levels in the cytoplasm) [138]. High levels of Ran- 
GTP in the nucleus favour binding of Ran-GTP with nuclear export signal containing 
proteins such as Crml-Rev-RRE which is very stable [148,150]. Once bound to Ran- 
GTP, the Crml-Rev-RRE complex is able to be transported out of the nucleus into the 
cytoplasm mediated by the GTP disparity energy gradient [150]. Once in the cytoplasm 
RanBPl binds Ran-GTP to catalyze the disassociation of the bound components (Crml- 
Rev-RRE). This allows Rev to re-enter the nucleus via the mechanism described above 
and continuously shuttle vRNA back into the cytoplasm [150] (Fig. ii). Once in the 
cytoplasm, RNA transcripts are translated through two different mechanisms: Either by 
the classical 5’ cap dependent translation initiation (less common), or through internal 
ribosomal entry sites (IRES) (more common) [151]. The classical 5’cap mechanism is 
maintained by all cellular proteins as well as HIV proteins which code for gag and pol 
[152-154], In this mechanism, the 5’ cap on the RNA transcript is recognized by the 
cellular factor eIF4E and leads to the unwinding of the secondary RNA structures by the
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eIF4A helicase. eIF4E also acts as a scaffold for the binding of eIF4G which coordinates 
the binding of 40S ribosome and the initiation of translation [155, 156]. IRES mediated 
translation initiation allows for direct recruitment of an initiation complex (either direct 
recruitment of the 40S ribosomal subunit, an IRES transacting factor, or by other 
initiation factors) near or at the AUG start codon [157]. Although there are no consensus 
sequences which are characteristic of IRESs, these sites are often structurally similar in 
that they contain a long and structured LTR and several AUG triplets [158].
Assembly
Incorporation of viral proteins into a maturing virion requires their transport to the 
cell membrane. Gag polyprotein shuttling to the cell membrane and virus formation 
requires 3 domains: 1) the membrane domain which is post-translationally myristoylated 
at the N-terminus of the matrix for interaction with the cell membrane. 2) The Interaction 
domain, which is found at the N-terminus of the nucleocapsid, promotes gag-gag 
interactions at the membrane and leads to oligomerization at the plasma membrane (PM). 
3) The PTAP motif or the late domain found on the N-terminus of p6 is necessary for the 
last stages of viral budding [159-162],
The membrane domain, along with highly basic residues, comprise a membrane 
targeting motif which interacts with acidic phospholipids on the PM [110]. The myristic 
acid addition to the matrix also allows gag to target lipid rafts on the PM. 
Phosphatidylinositides (PI) are a class of phosphorylated fatty acids which are implicated 
in cellular trafficking to various organelles. The Pis PI(4)P, PI(4,5)P2, and PI(3,4,5)P3
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Fig. ii Rev shuttling. Once translated in the nucleus, Rev binds importin p and Ran-GDP to 
re-enter the nucleus. Once RCC1 performs GEF activity on Ran-GDP converting it to Ran- 
GTP, rev and importin p dissociate. Rev is then able to bind RRE of HIV mRNA, CRM1 
nuclear exporter, and Ran-GTP. With increased Ran-GTP in the nucleus, rev uses the GTP 
energy gradient generated across the nuclear membrane to export HIV mRNA into the 
cytoplasm. Hydrolyzation of Ran-GTP in the cytoplasm by RanGAP and RanBpl leads to 
the dissociation of the Rev complex and HIV mRNA is able to be translated.
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are able to target to the PM and thus proteins that interact with these Pis are also 
trafficked to the PM. In particular PI(4,5)P2 is a major PI for PM trafficking and 
regulates a variety of membrane events such as endocytosis, exocytosis, synaptic vesicle 
trafficking etc. Gag trafficking to the PM is thought to exploit PI(4,5)P2 to get to the PM. 
In particular PI(4,5)P2-gag preferentially targets lipid rafts on the PM [178]. Lipid rafts 
preferentially interact and incorporate saturated fatty acids. The myristic acid 
modification of gag is a highly saturated fatty acid and is therefore incorporated into the 
raft. As gag is continually transferred to the membrane, gag-gag interactions are formed 
through the Interaction domains of the gag polyproteins [161].
Pol exists only with the coexpression of gag in a large gag-pol polyprotein. 
However, gag-pol requires the assistance of the gag polyprotein to shuttle to the PM.
Gag and gag-pol polyproteins interact in the cytoplasm through the major homology 
region in the capsid region. Gag-pol therefore hitchhikes to the PM with the assistance 
by binding directly to myristoylated gag and targeting to the cell membrane [179], 
Interestingly, gag-pol is not the only viral protein which uses gag to assist in membrane 
trafficking. Vpr directly binds the p6 region of gag to promote its incorporation into the 
maturing virion [180,181]. In addition, HIV genomic RNA contains 4 stem loop 
structures (SL1-4) known as a psi-site (\|/) which is recognized by the nucleocapsid of gag 
polyprotein and allows for packaging of genomic RNA into the virion. SL2 and SL3 are 
the main binding determinants of y  and interact with the nucleocapsid through zinc finger 
binding [182-184], SL1 is necessary for genomic RNA dimerization whereas SL4 is 
necessary for stabilization of the tertiary structure of \\i [185,186].
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To form the mature structural components, gag and gag-pol precursor 
polyproteins must be cleaved by the viral protease (PR) located in the pol region of gag- 
pol. Activation of the protease occurs when dimerization of the PR domains of gag-pol 
leading to intramolecular cleavages (ie. The PR domains of each gag-pol cleave different 
processing sites within the gag-pol precursors that make up the dimer) [111, 112]. 
Through autocatalytic processing, the PR cuts itself out of the polyprotein by cleaving 
peptide bonds at either ends of its sequence [187,188]. After being released, the PR 
continues to cut peptide bonds within the gag-pol polyprotein to release the RT, IN, and 
the structural components of the virus (matrix, capsid, nucleocapsid, p6) [189].
The transmembrane envelope glycoprotein gpl60 is the precursor protein of the 
proteolytically cleaved glycoproteins gpl20 and gp41. Gpl60 oligomerizes in the 
endoplasmic reticulum as a trimer (predominantly) and is then transported to the cell 
membrane via the secretory pathway. During its trafficking through the golgi, it is 
cleaved by the host protease, furin to produce gpl20 and gp41 which form a fusion 
complex together through non-covalent interactions [116-118]. The mechanism by which 
gp41/gpl20 is incorporated into the maturing virus is not fully understood, however it has 
been suggested that the cytoplasmic tail of gp41 recognizes the matrix domain of gag and 
allows for its incorporation into virions [114,115].
Budding and Maturation
The late domain on p6 of gag contains a PTAP motif that is recognized by the 
cellular factor TSG101 which also binds to another PTAP domain of AIP1 and a number 
of additional proteins to make up the ESCRT-I complex [190,191]. The AIP1 of the
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ESCRT-I complex interacts with CHMP4 proteins which oligomerize at the PM and 
make up the ESCRT-III complex [191,192], ESCRT-III proteins interact with an ATPase, 
VPS4. The N-terminus of VPS4 is responsible for the binding of ESCRT-III complex 
whereas the C-terminus contains a (3-domain which interacts with the protein LIP5 [194], 
VPS4 functions as a hexameric ring in which the N-termini are central to the ring and the 
P-domains are on the perimeter. When two VPS4 hexameric rings are stacked, they 
attain full enzymatic function and disassemble the ESCRT-III complex which provides 
energy for membrane fission [193], However, the precise mechanistic details remain to 
be elucidated.
Maturation of the viral particle occurs when gag and gag-pol are cleaved to form 
their mature structural and enzymatic forms. Cleavage of these polyproteins is performed 
by the viral protease but it is unclear whether this occurs during the budding process or 
whether it happens after budding in the immature virion [189].
1.5 Interferon Response
Interferon (IFN) is an indispensible mechanism of defence against viral infection 
in vertebrates. Mice that lack a subunit of the IFN receptor (IFNR) quickly succumb to 
viral infections despite having a normal adaptive immune system [119]. Two pathways 
exist that lead to the upregulation of IFN in response to viral infection: the classical 
pathway and toll-like receptor (TLR) pathway. The classical pathway is used by 
fibroblasts, hepatocytes, and conventional dendritic cells which detect viral infection 
through the use of cytoplasmic receptors that recognize viral components and upregulate 
the transcription factors IRF3 and NF-kB to activate IFN-[3 gene expression [124], For
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example, the dsRNA sensors MDA5 and RIG-I are expressed ubiquitously across most 
tissues and are upregulated in response to IFN. Subsequently, upon sensing dsRNA, 
RIG-I and MDA5 amplify the production of IFN [120, 123]. The TLR mediated pathway 
is mediated by plasmacytoid dendritic cells which are strong producers of IFNa. These 
are strong sensors of DNA viruses and RNA viruses through the use of TLRs found in 
endosomes. HIV infection is recognized by cells through the sensation of intracellular 
ssRNA by TLR 7 and 8 [121, 125]. Activation of these TLRs causes the formation of a 
complex between their adaptor molecule, MyD88 and TRAF6 and IRF7. IRF7 is 
phosphorylated by IRAK-1 which leads to its activation and expression of IFNa [122] 
(Fig. iii a). IFNs are cytokines which modulate cell growth, activate other antiviral 
cytokines, and promote an antiviral response. IFN ot/(3 are sensed by the IFNR which is 
comprised of two major subunits, Interferon alpha receptor subunit 1 (IFNAR1) and 
IFNAR2 [126,127]. Binding of type I IFNs causes the two subunits to associate which 
leads to the phosphorylation, dissociation, and activation of Tyk2 and JAKlat the 
cytoplasmic domain of IFNR. This allows for binding of STAT1 and STAT2 on 
IFNAR1 on which they are phosphorylated and subsequently translocate into the nucleus 
where they associate with the DNA binding protein p48 [128, 129]. This heterotrimer is 
known as ISGF3 which bind ISRE (IFN stimulated response element) of the IFN a/(3 
genes. This leads to the upregulation of over 300 IFN stimulated genes such as antiviral 
restriction factors (Fig. iii b).
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Fig. iii Interferon signalling. A) recognition of ssRNA by TLR7 or 8 causes a 
signalling cascade that activates transcription factors IRF7 and NF-kB and lead to the 
upregulation of type 1 IFN cytokines. B) Interferon a/p are recognized by type 1 
interferon receptor composed of INFAR1/INFAR2. This causes the phosphorylation 
and dissociation of Tyk2 and Jakl and association of STAT1 and STAT2. These are 
phosphorylated and translocate to the nucleus where they bind to the DNA binding 
protein p48. This leads to the upregulation of a number of antiviral restriction factors 
including Herc5 and ISG15.
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1.51 Restriction Factors
In response to a viral infection and IFN stimulation, host cells upregulate a 
number of proteins to control viral replication known as restriction factors. In response to 
HIV, PKR is able to restrict translation. Again after binding the TAR element, PKR 
phosphorylâtes the protein eIF2a which is normally involved in the transfer of met-tRNA 
to the 40S ribosome for translation. Phosphorylation of eIF2a restricts its ability to 
transfer the start codon to translating proteins thus restricting all protein production [163- 
165]. OASl/RNaseL also inhibits translation of HIV by recognizing dsTAR RNA [167]. 
Once activated OAS1 forms a tetramer which breaks down ATP into 2-5 oligoadenylates 
which are strong activators of RNaseL [167,168]. The RNaseL enzyme degrades all 
ssRNA in the cell including mRNA thereby restricting all translation including viral 
translation [166-168],
Other viral restriction factors include the TRIM family of proteins; a number of 
which have been shown to be able to restrict HIV. TRIM5a is able to prevent HIV viral 
uncoating in the cytoplasm by binding to the viral core and preventing the degradation of 
the capsid thus inhibiting the unpackaging of the RNA genome [169], TRIM22 has been 
shown to restrict HIV by inhibiting the release of gag polyprotein (which is able to 
release from cells without any other viral proteins) and preventing the accumulation of 
gag at the cell membrane though the precise mechanistic details behind TRIM22 
restriction of HIV need to be elucidated [170,171].
1.52 Interferon Stimulated Gene 15 (1SG15)
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Interferon stimulated gene 15 (ISG15) was the first ubiquitin like modifier 
discovered and is strongly upregulated in response to type I interferon production and 
viral infection in vertebrate species [172]. Similarly to ubiquitin, ISG15 is a 
posttranslational modifier of proteins that requires an E3 ligase, an El enzyme, UbelL 
and an E2 enzyme, UbcH8. The El enzyme, UbelL recognizes ISG15 and passes it to 
the E2 enzyme through a transthiolation reaction. When ISG15 is bound to the E2, 
UbcH8, they bind to the E3 ligase which also binds the protein substrate and facilitates 
ISG15 conjugation to the substrate [175-177]. ISG15 contains two ubiquitin-like 
domains at the N-terminus and C-terminus which are connected by a central hinge region 
made up of 5 beta sheets and 1 alpha helix (Fig. iv). The C-terminus is predicted to be 
the main point of interaction with its E l enzyme UbelL, specifically through the residues 
K90 (lysine), W123 (tryptophan), and F149 (phenylalanine) [54], The C-terminus also is 
required for the transfer of ISG15 from UbeEL to the E2 enzyme, UbcH8, which is 
mediated by transthiolation reactions. The N-terminus however is predicted to be 
responsible for the E3 mediated transfer from the E2 enzyme, UbcH8, to the target 
substrates [55], There are currently two well known E3s for ISG15 conjugation, the main 
ISG15 conjugator being the HECT domain and RCC-1 like domain containing protein 5 
(Herc5) and Estrogen-responsive finger protein (EFP) [195,196]. As a response to IFN 
stimulation and defence against viral protein expression, Herc5 has been shown to 
associate with the 60S subunit of polyribosomes (groups of ribosomes bound to mRNA) 
and broadly ISGylates newly synthesized proteins in an attempt to inhibit vims assembly. 
Although ISGylation of a broad range of newly synthesized proteins is relatively 
inefficient, it is believed that this is beneficial to the host cell to minimize excessive
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Fig. iv The crystal structure of ISG15. Two ubiquitin -like domains are joined at a 
central hinge region. C-terminus is necessary for binding the El enzyme, UbelL and 
the transfer to E2 enzyme, UbcH8. The N-terminus is required for E2 transfer to the 
E3 ligase and target substrate [54],
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damage to host proteins. In addition, structural proteins of viruses often require very 
precise gefometric configurations to form infectious particles; ISGylation of even a small 
portion of these viral proteins may lead to the restriction of virus production [62],
ISG15 is able to act as a restriction factor against HIV budding by interfering with 
the interaction of TSG101 with the p6 domain of gag although neither protein is directly 
modified with ISG15 [173]. ISG15 is also able to interfere with Vps4 recruitment to the 
ESCRT-III complex. Although this mechanism is not fully elucidated, it is believed that 
ISG15 binds to components of ESCRT-III and prevents Vps4 recognition of the complex. 
The result of such restriction leads to the formation of “lollipop” structures on the surface 
of infected cells where virus is unable to be pinched off and released from the cell [174],
It is unclear what the physiological significance of ISG15 conjugation is. 
However, experiments determining ISGylatable proteins have been performed to help 
elucidate its relevance. The proteins JAK1 and STAT1 were among the first proteins to 
be discovered which can be ISGylated. Both JAK1 and STAT1 are key components of 
the interferon activating pathway. It is possible that ISGylation of these proteins in the 
interferon signal transduction pathway is a method of regulating the expression of 
interferon either positively or negatively [56,57]. Since ISG15 is upregulated within the 
first 24 hours in response to cellular stressors and pathogens, it is believed that ISG15 is 
involved predominately in innate immune responses. However, it has also been shown to 
be involved in a diverse range of cellular processes such as protein trafficking and 
cytoskeleton organization [58].
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Studies show that ISG15 can also target and conjugate to the Influenza A NS1 
protein after type I interferon treatment. The NS1 protein of Influenza A is able to 
interfere with host mRNA processing and is also able to shut off a number of cellular 
defences against virus infection such as OAS1 ISGylation of the NS1 protein has shown a 
robust ability to inhibit vims replication. Krug and colleagues found that K41 is the 
predominant residue for ISG15 conjugation of NS1. This region of NS1 is responsible 
for binding dsRNA in order to block the activation of a number of different antiviral 
proteins which are activated by the recognition of dsRNA, a pathogen associated 
molecular pattern. It is thought that ISG15 conjugation in this region of NS1 would 
block NS1 from binding to dsRNA and allow for greater antiviral activity within the cell 
[63],
Hepatitis C Vims (HCV) replication is also strongly diminished with interferon 
induction and ISG15 overexpression. The NS5A protein of HCV is ISGylated at K379 of 
the C-terminal region which subsequently leads to protein instability. The mechanism of 
restriction is again unclear. Experiments with NS5A conjugated with ISG15 show that 
the NS5A protein is not being degraded by the 26S proteasome. However, it was shown 
that NS5A was both ubiquitinated and ISGylated and that these two in parallel were 
involved in altering the proteins’ stability [64],
Interestingly, ISG15 also exists as a soluble protein which can be excreted into 
extracellular space as an immunomodulatory cytokine upon stimulation of type I 
interferons. Secretion of ISG15 as a cytokine was shown to enhance NK cell and 
lymphocyte proliferation and killing. ISG15 is secreted by non-hematopoetic cells and 
predominantly secreted by peripheral blood mononuclear cells (PBMCs). ISG15 may be
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acting as a signal of cell stress or cell damage. It is possible that ISG15 found in 
extracellular fluid may be the product of cell death and is behaving as a danger associated 
molecular pattern rather than a secretory product [61].
The over expression of the ISG15 El protein, UbelL, has been shown to help 
control the development of lung cancer by inhibiting the growth of bronchial epithelial 
cells and lung cancer cells. This may be due to UbelL promoting ISGylation of cyclin 
D1 and causing its destabilization and abrogates cell cycle [59].
However ISG15 has also been reported to be an oncogenic factor. Many different 
tumors and tumor cell lines have displayed ISG15 disregulation and elevated levels of 
ISG15. This may be due to constitutively activated NF-kB found in many tumor cells 
which in turn continuously produces interferon and subsequently ISG15. In tumor cells 
where ISG15 is constantly elevated, polyubiquitination and degradation is strongly 
diminished however the mechanism by which ISG15 impairs ubiquitin conjugation 
remains to be elucidated. It is possible that ISG15 competes for the same lysine residues 
as ubiquitin on many different target substrates or that certain E l, E2s, and/or E3s that are 
common between ISG15 and ubiquitin are being sequestered or degraded by ISG15 [60],
Oddly, many of ISG15’s antiviral activities have been not been examined in the 
presence of its main conjugator, Herc5. Thus studying the effect of Herc5 in the context 
of a variety of viral infections is very important for determining whether Herc5 is also 
able to act as a potent viral restriction factor.
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1.6 HECT domain and RCCl-like domain containing protein (Here) Family
The Here family of proteins are made up of 6 members that possess a ubiquitin 
HECT domain (described in section 1.2) as well as an RLD [197,198] (Fig. v). The RLD 
structurally resembles the protein RCC1. Both the RCC1 and the RLD of Here proteins 
have a 7 bladed (3-propeller configuration where each blade is made up of 4 (3-sheets (Fig. 
vi) [199,200]. The RCC1 protein interacts with Ran in the nucleus to catalyze the 
conversion of Ran-GDP to Ran-GTP as a guanine nucleotide exchange factor (GEF).
The GTPase function of RCC1 is necessary for the generation of a GTP energy gradient 
in the nucleus for the export of mRNA to the cytoplasm (the same pathway that is 
hijacked by rev) [201-203]. The activity of RCC1 has also been implicated in nuclear 
envelope assembly, mitotic spindle formation, and cell cycle regulation [204]. RCC1 
activation depends on its binding to nuclear chromatin particularly at histones 2A and 2B. 
Thus, RCC1 is able to interact with Ran on one face of the |3-propeller while it tethers to 
nuclear chromatin on the other [200], Of the RLD containing Here proteins, H erd has 
displayed GEF activity in its RLD1 whereas the RLD domain of Herc3 displays none. It 
remains to be determined whether the other members of the Here family maintain an 
RCCl-like GEF function [205].
The Here family is separated into two subgroups based on their size and domain 
architecture. Here 1 and Herc2 belong to the large Here family where each is roughly 
530kDa. Interestingly, these two Here proteins also contain multiple RLDs, H erd  with 
two RLDs and Herc2 with three [206], Although not much is known about these proteins, 
it is thought that H erd  may have oncogenic properties as it is over expressed in a number 
of tumor cell lines. It is also possible that H erd  is involved in membrane trafficking to
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the golgi [205], Hercs 3-6 belong to the small Here family whose sizes are 
approximately 120kDa [206]. Phylogenetic studies on the Here family suggest that 
Herc4 may be the most ancient of the proteins from which all other Hercs derived as it is 
found in the nematode genome [198]. From such studies, Herc5 seems to be the newest 
addition to the Here family [198].
1.61 Herc5
Herc5 is a type 1 interferon induced protein comprised of three major domains, 
the RLD, a spacer region, and an E3 ligase HECT domain. Currently, the HECT domain 
is the most well characterized region of Herc5 as it has been identified as the catalytic 
domain for ISG15 conjugation. Herc5 functions in conjunction with the El enzyme 
UbelL and the E2 enzyme UbcH8 to conjugate ISG15 to target substrates [207], These 
proteins are upregulated by type 1 interferons (Herc5 is upregulated 5 fold) which 
suggests the pathway may play an important role in innate immunity [208]. This activity 
has been described largely in terms of antimicrobial activity even though the 
physiological relevance of ISG15 conjugation has yet to be determined in this context. A 
cysteine residue at position 994 in the HECT domain is crucial to Herc5’s ability to 
conjugate ISG15 to targets [208]. It has been shown that ISG15 conjugation at the RNA 
binding domain Influenza A Virus NS1 by Herc5 is able to attenuate virus propagation 
and virulence by inhibiting the interaction with Importin a and blocking nuclear import of 
the NS1 protein [209,210, 216]. Although Herc5 has not been directly identified in a 
number of antiviral activities, ISGylation has been shown to restrict Sindbis virus, Herpes 
simplex 1, HIV-1, and Ebola. In addition, Herc5 ISGylation has been shown to enhance 
the production of type 1 interferons by ISGylating interferon regulatory factor 3 (IRF3)
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Fig. v Here family of proteins is divided into two groups, the large and small Hercs. Both 
H erd  and Herc2 belong to the large family of Here proteins roughly 530kDa and contain 
multiple RLD domains. Herc3-6 all belong to the small Here family and are roughly 120kDa 
[222],
-34-
RCC1 Herc5 RLD Fit
Fig vi. Herc5 RLD vs. RCC1- RCC1 and Herc5 RLD both contain 7 bladed propellers 
made up of 4 (3-sheets. Although the amino acid sequences are only slightly homologous, 
the structural homology is almost identical as depicted in the Fit panel in which both RCC1 
and Herc5RLD are overlapped. (Courtesy of Stephen Barr)
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and sustaining its function [177], This suggests Herc5 may have broader antiviral 
activities than it is accredited for and thus act as a potent and versatile viral restriction 
factor.
The spacer domain of Herc5 shows no homology to any known protein. However, 
through predictive modelling, it is likely to be abundant in alpha helices similarly to 
coiled coil domains. Coiled coil domains are important to many intermolecular 
interactions including the formation of protein oligomers [212]. For example, gp41 of 
HIV requires coiled coil interactions to adhere to the cell membrane [213]. The 
ISGylating E3 ligase EFP contains a coiled coil domain which has been shown to be 
important for autoISGylation and the interaction with its substrates [214]. It is possible 
that the spacer region of Herc5 acts in a similar manner as EFP and acts as a binding 
domain for Herc5 substrates or as a location for autoISGylation however further 
characterisation of the protein is required to determine the functional role of this domain.
The RLD of Herc5 shares roughly 35% sequence homology with RCC1 however 
predictive modelling of the Herc5 RLD shows almost complete structural identity with 
RCC1 (Fig. vi). This raises the question whether the RLD of Herc5 has similar functional 
behaviour as RCC1 as a GEF. Like RCC1, Herc5 has been implicated in the regulation 
of cell cycle. Herc5 was shown to interact with the cyclin E-Cdk2 kinase which is 
indispensible for the transition of G1 to S phase. Herc5 is also highly expressed when the 
tumor suppressor proteins Rb and p53 are inhibited [215], It is possible that Cyclin E- 
Cdk2 is recognized by the RLD and ISGylated by the HECT domain which stabilizes or 
degrades the complex to regulate cell cycle progression.
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As mentioned under the HECT E3 ligase section (appendix), the N-termini of E3 
ligases predominately function as the binding domains for target substrates [10-12], 
Therefore, it is possible the RLD may also act as the binding domain for Herc5 substrates 
Mutational studies in which the RLD of Herc5 has been removed, ISGylation was shown 
to be drastically reduced but not completely abolished [208], In addition, Herc5 binding 
to NS 1A protein is eliminated when the RLD is removed [216],
ISG15 has been implicated in many antiviral activities, including the restriction of 
HIV-1 at the late stages of virus release. However, many of its antiviral properties have 
not been investigated in the context of its main E3 conjugating ligase, Herc5. Thus far, 
Herc5 has only been directly implicated in antiviral activity through the restriction of 
both Influenza A and B and is also upregulated during the course of Hepatitis C infection 
[209,210,216,219], However, it is also upregulated 4 fold in the presence of type 1 
interferons and positively regulates their expression by modifying interferon regulatory 
factor 3 (IRF3) with ISG15 [211], Herc5 also broadly ISGylates newly synthesized 
proteins upon type 1 interferon signalling [62], The potency of ISG15 as a viral 
restriction factor and the implications of Herc5 in a variety of antiviral activities strongly 
suggest that Herc5 may in fact have greater potential for restricting viral replication than 
what is currently understood. Further investigation into the antiviral properties of Herc5 
as a restriction factor must be conducted to better understand the physiological relevance 
of Herc5 during viral infection in hopes of extrapolating its activity for novel antiviral 
therapies.
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1.7 Preliminary data
Our lab has shown that Herc5 mediated ISGylation of the HIV-1 gag structural 
protein is sufficient to restrict the release of virus-like particles (gag polyprotein release) 
from U20S cells. The C994A Herc5 mutant that lacks E3 ligase activity is unable to 
restrict gag release. Herc5 transfected cells co-transfected with Ubp43, a delSGylating 
enzyme, are also unable to restrict gag release. This suggests that ISGylating activity of 
Herc5’s HECT E3 ligase domain is responsible for inhibiting gag budding from cells (Fig. 
vii).
When cells are infected with replication competent HIV in the presence of Herc5, 
there is restriction of HIV-1 release from the cell as well as restriction of gag protein 
production in the cell. When C994A Herc5 is transfected into HIV infected cells, there is 
still restriction of gag production in the cell and virus release (Fig. viii). This indicates 
that the E3 ligase activity of Herc5 is not absolutely necessary for virus restriction and 
that there are two mechanisms by which Herc5 can restrict viral replication -  although it 
is unclear what the second mechanism is. Therefore, characterizations of the RLD and 
spacer regions are required to understand the second mechanism of HIV restriction.
Quantification of intracellular gag mRNA in cells infected with HIV-1 indicates 
that in the presence of Herc5 there is a build up of gag mRNA that is not being translated 
into protein in comparison to the negative control (3.5x more gag mRNA) (Fig. ix). It is 
possible that mRNA is not being translated because there is a defect in mRNA shuttling 
to the cytoplasm.
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Fig. vii HERC5 ISGylation leads to gag polyprotein restriction in U20S cells. A) gag
transfected into U20S cells in the presence of Herc5, C994A, or negative control. Gag virus 
like particle release was measured by western blot detection of gag polyprotein using gag 
antibody. B) Western blot of gag release in Herc5 transfected cells and ISG15 conjugation 
system in the presence or absence of de-ubiquitinating protein Ubp43. (Courtesy of Matt 
Woods; Woods, M., et al., 2011. Unpublished)
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Fig. viii Herc5 restriction of HIV-1. pGL3, WT Herc5, or C994A, was co-transfected with 
replication competent HIV-1 (R9) in U20S cells. Herc5 and C994A are able to restrict the 
release of virus into cell supernatant. Herc5 and C994A are also shown to restrict gag 
polyprotein production in the cell pellet in the presence of R9. (Courtesy of Matt Woods; 




Fig. ix qRTPCR of gag mRNA in HIV-1 infected cells. qRTPCR of gag mRNA in HIV-1 
infected U20S cells co-transfected with Herc5 or pGL3. 3.5x fold increase in gag mRNA in the 
presence of Herc5. (n=3) (Courtesy of Matt Woods; Woods, M., et al., 2011. Unpublished)
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1.8 Hypothesis and Aims
I hypothesized that the spacer and/or RLD domains of Herc5 were necessary for 
Herc5 mediated HIV-1 restriction since elimination of HECT domain activity did not 
abolish Herc5 restriction of HIV-1. I also hypothesized that the Spacer or RLD is 
interrupting proper export of mRNA from the nucleus to the cytoplasm. To approach my 
hypothesis the specific aims of the project were: 1) to generate domain deletions of the 
RLD and spacer domain as well as individual bladed deletions of the RLD region of 
Herc5, 2) To determine whether the RLD or spacer domains were required for HIV-1 
restriction using the mutants generated in aim 1,3) to explore the effects of these deletion 
on the physiology of the host cell.
Chapter 2: Materials and Methods
2.1 Plasmid Constructs
RLD mutants via digestion, ligation, transformation- the wild type Herc5 
construct in CS2+ plasmid backbone was generously supplied by K. Chin at Genome 
Institute of Singapore. This construct was used to subclone all mutants of Herc5 into the 
pFLAG plasmid backbone. Various mutations of the Herc5 RLD were generated using 
primers recognizing the sequences encoding each blade of the RLD creating increasingly 
larger truncations of the domain. All forward primers included the Bglll restriction site 
and all reverse primers included Xbal restriction sites. Primers and template were used in 
PCR reactions to amplify the tmncated forms of Herc5 lacking blades of the RLD (Fig. x). 
Primer sequences used for the generation of pFLAG RLD mutants can be found in 
Supplementary Table 1. PCR conditions used to amplify the RLD truncations to be
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incorporated in pFLAG are found in Supplementary Table 2. PCR products were then 
purified using spin column PCR purification (Invitrogen and BioBasic) and used in single 
enzyme digests with both Bglll and Xbal using buffers3 and buffer 2 respectively (New 
England Biolabs). Digests were done for 2 hours at 37°C and purified after each digest. 
After digestion of pFLAG vector with Bglll and Xbal, digested DNA and vector were 
ligated using T4 ligase (New England Biolabs) for 20 minutes at room temperature. The 
product was then transformed into DH5a competent cells and grown on LB agar plates 
containing ampicillin overnight (16 hours) at 37°C. Bacterial colonies grown were 
screened for insert by extracting plasmid DNA with Purelink Quick Plasmid Miniprep 
Kit (Invitrogen). Products were digested with a single enzyme (Xbal or Bglll), and run 
on an ethidium bromide 1 % agarose gel with a 1 Kb ladder. Lanes with an appropriately 
sized DNA product (insert + product= ~7.5Kb -  8 Kb) were sent for DNA sequencing for 
additional sequence verification at Robarts Research Institute.
RLD mutants and spacer mutant created with modified site directed mutagenesis and 
transformation- RLD deletion constructs and the spacer deletion mutant were made using 
modified site directed mutagenesis and designed to be expressed in the CS2+ plasmid 
vector. WT Herc5 in pCS2+ vector was generously provided by K. Chin at the Genome 
Institute of Singapore, from which all RLD and spacer deletions were subcloned.
Primers were designed to recognize sequences directly before and after the region to be 
deleted (Table i). pCS2+ plasmid map is included in Supplementary Figure 2. The 
QuikChange® Lightning Site-Directed Mutagenesis Kit and its corresponding protocol 
were used for the PCR amplification of the RLD and spacer mutants of Herc5 (Table ii). 
After amplification, PCR products were digested with Dpnl enzyme (40 units per reaction)
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at 37°C for 5 minutes to digest methylated, supercoiled parental dsDNA and isolate 
desired Herc5 mutants. Digested products were then transformed into XL-10 Gold 
ultracompetent cells. 45ul of ultracompetent cells were added to 14ml round-bottom 
tubes and supplemented with 2ul of P-mercaptoethanol mix (provided with cells). This 
was incubated on ice for 2 minutes after which 3ul of Dpnl (60 units) digested PCR 
amplified Herc5 mutated DNA was added to the cells. This mixture was incubated on ice 
for 30 minutes and then heat pulsed at 42°C for 30 seconds. The reaction was then 
placed back on ice for 2 minutes. 0.5ml of preheated (42°C) SOC media (0.5% Yeast 
Extract, 2% Tryptone, lOmM NaCl, 2.5mM KC1, lOmM MgCL, lOmM MgSCL, 20mM 
Glucose) was then added to each tube and incubated at 37°C for 1 hour while shaking at 
225rpm. 300ul of each reaction was plated on ampicillin agar plates and left at 37°C 
overnight (>16 hours). Colonies obtained from incubated plates were then screened for 
desired inserts (mutated Herc5 constructs). Colonies were picked and grown in 1.5ml of 
LB broth supplemented with lOOuM of ampicillin overnight (>16 hours). Resulting 
bacterial suspensions were pelleted and miniprepped using BioBasic™ EZ-10 spin- 
column plasmid DNA minipreps kit to extract transformed plasmid. The resulting 
product was then quantified using Implen nanophotometer to determine DNA 
concentration. 300ng of product was loaded on a 1 % Ethidium Bromide (EtBr) agarose 
gel and run at 120 volts for 45 minutes alongside a 1Kb DNA ladder. Products 
corresponding to the approximate size of product and insert were sent to Robarts 
Research Institute where they were sequenced verified. Confirmed mutants were then 
maxiprepped with Qiagen® plasmid maxi kit and ready for transfection.
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Fig. x RLD mutant design. A) Mutations of the RLD were designed to delete sequentially 
greater portions of the domain. 7 mutants of the RLD were originally intended, each deleting 
one blade more of the RLD than the last. B) Primers recognizing the start of the different 
RLD blades were designed and used for PCR amplification of the different Herc5 RLD gene 
products. PCR products were run on a 1 % agarose gel and visualized using ethidium bromide 
staining. Al, Al-3, ARLD were successfully cloned into pFLAG; Al-2, Al-4, Al-5, Al-6 DNA 
inserts were unable to be cloned into pFLAG. Primer sequences can be found in 
Supplementary Table 1.
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Table i. Primers used for pCS2+ Herc5 RLD mutants and Spacer domain deletion.
Primers are made up of sequences before and after region to be deleted and omit the 
sequence of the area being deleted. Bold segments bind to the region after the region 
deleted (head), while the non bold sequences bind the region before the region to be 
deleted (tail).
Deletion Forward Primer Sequence Reverse Primer Sequence
ARLD 5 ’ GACATG GAG CGC CGC 
AGC  ATG ATT GCT GGA 
GGG AAT CAA AGC ATT 
TTG CTC TGG 3’
5’ GCT TTG ATT CCC TCC AGC 
AAT CAT GCT GCG GCG CTC 
CAT GTC GTC3’
A1-2RLD 5 ’ GACATG GAG CGC CGC 
AGC  CAG GGA GCC GAA 
CAC ATG CTG 3’
5’ GTG TTC GGC TCC CTG GCT 
GCG GCG CTC CAT GTC GT 3’
A1-5 RLD 5 ’ GACATG GAG CGC CGC 
AGC GAT GGG CTG CTG 
TTT ACT TTC GGT GC 3’
5’ AGT AAA CAG CAG CCC ATC 
GCT GCG GCG CTC CAT GTC 
GTC 3’
Aspacer 5’ ATG ATT GCT GGA GGG 
AGG CCC ACG TTT GAT 
CTA ACA GTC AGA AGG 3’
5’ GAC TGT TAG ATC CCC TCC 
AGC AAT CAT TAT TAA CTC 
CTT TTC TGA GG 3
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Table ii. PCR conditions for pCS2+ Here mutants. A) Conditions for amplification of 
pCS2+ Herc5 RLD mutants and Spacer deletion mutants B) Thermocycling conditions 
required for amplification of RLD and Spacer mutants
5ul lOx Reaction buffer
120ng dsDNA template (pCS2+ Herc5)









Temperature Time # of cycles
Initial Denature 95°C 2 minutes lx
Denature 95°C 20 seconds 18x
Annealing 60°C 10 seconds 18x
Extension 68°C 4 minutes 18x
Final Extension 68°C 5 minutes lx
- 4 7 -
2.2 Cell culture, plasmids, and transfection
U20S, HeLa, 293T and HOS cells were cultured at 37°C and 5% C02 in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 100IU penicillin/ lOOug/ml streptomycin. Cells for all experiments were seeded in 
either 6-well dishes containing 2ml of DMEM or in 12-well dishes (BD Biosciences) 
containing 1ml of DMEM. Herc5 constructs were described previously.
2.21 Transfections
Lipofectamine transfection
Lipofectamine 2000 (Invitrogen) was used for single or dual plasmid transfection of 
plasmids. A total of 2ug of DNA and 4ul of lipofectamine were transfected into 12-well 
dishes of HeLa cells at 90% confluency and a total of 4ug of DNA and lOul of 
lipofectamine were transfected into each 6-well 10cm well (BD Biosciences). Protocol 
included in the kit was followed without modifications. Lipofectamine was used for all 
confocal microscopy experiments and HIV release assay.
FuGene transfection
FuGene® HD (Roche) was used for single plasmid transfection of HeLa cells at 70% 
confluency. 2ug of DNA and 4ul of FuGene were used for each 6-well, 10cm2 well. 
Protocol included in the kit was followed without modifications. FuGene was used for 
RTPCR transfection experiments for mRNA expression of Herc5 construct and 
propidium iodide staining for cell cycle analysis
SuperFect Transfection
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SuperFect (Qiagen) was used for single plasmid transfection of HeLa cells at 90% 
confluency. 2ug of DNA and lOul of SuperFect transfection reagent were used for each 
6-well, 10cm2 well. Protocol included with the kit was followed without modifications. 
SuperFect was used for growth comparison experiment between the different Herc5 
construct transfected cells.
2.3 mRNA expression of protein constructs
6-well plates of U20S were transfected with FuGene® at 70% confluency. Cells 
were harvested after 24 hours and RNA extraction was performed using PureLink™
RNA Mini Kit (Invitrogen). RNA was then reverse transcribed using M-MLV Reverse 
Transcriptase (Invitrogen). The protocol supplied with reverse transcriptase was not 
altered. cDNA was then used to amplify various Herc5 mutants using PCR. lOul of 
products were then run on a 1% agarose gel next to a 1Kb DNA ladder (New England 
Biolabs) (Table iii).
2.4 HIV-1 release Assay (performed by Matthew Woods)
6-well plates of U20S cells were co-transfected with replication competent HIV-1 
(R9 plasmid) and one Herc5 construct using lipofectamine at 70% confluency. 1ml of cell 
supernatant was collected 48 hours later and stacked on top of 300ul of 20% sucrose. 
Supernatant was spun at 14000g for 2 hours to collect extracellular virus. Cell pellets 
were also collected after 48 hours. Once the supernatant was collected, both cell pellet 
and supernatants were lysed (separately) using RIPA lysis buffer and run on a 10% SDS 
page gel. Detection of capsid protein and gag polyprotein were done using anti-p24 
antibody. Mouse IRDye 680 secondary antibody (LiCOR) was used to illuminate
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primary antibody bound to p24 protein and rabbit IRDye 800 antibody (LiCOR) for actin 
control.
2.5 Growth analysis of Herc5 construct transfected cells
6-well plates of HeLa cells were transfected at 90% confluency using SuperFect 
transfection reagent (Qiagen) with one of the Herc5 constructs according to the 
specifications outlined in the included protocol. Three hours after transfection, cells were 
harvested and 250000 cells were seeded into each well of ten 12-well dishes (two dishes 
were needed to count each day for growth comparison between constructs for a total of 4 
days). For each Herc5 construct, 3 wells were seeded (done in triplicate) for each day the 
experiment was to be carried out (a total of 12 wells were seeded for each construct).
Each day, 3 wells were counted using a hemocytometer for each construct and growth 
was monitored over 4 days. Growth rates of cells transfected with the different Herc5 
constructs were compared to the negative control transfected (pGL3) cells and 
statistically analyzed using two-way ANOVA.
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Table iii. PCR conditions for RTPCR of Herc5 CS2+ mutants. A) Conditions used 
for PCR reaction performed for RTPCR of Herc5 construct mRNA. B) Thermocycling 
conditions needed for amplification of Herc5 construct cDNA
A.
5ul lOx Pfu buffer
6ul M gS04
lui lOmM dNTPs
lui Forward primer (fwd spacer primer)







Temperature Time # of cycles
Initial Denature 95 °C 3 minutes lx
Denature 95 °C 30 seconds 32x
Annealing 50.5°C 30 seconds 32x
Extension 72°C 4 minutes 32x
Final Extension 72°C 10 minutes lx
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2.6 Confocal Microscopy
Hela cells were seeded in 6-well dishes and transfected using lipofectamine 2000 
at 90% confluency. After 24 hours, cells were harvested with PBS EDTA and 3.5x10s 
cells were transferred into 12-well dishes with 18mm coverslips and fresh media. 24 
hours after, cells were washed with lxPBS /1%FBS twice and fixed with a fixing buffer 
for 10 minutes (19ml lxPBS, 1ml Formaldehyde, 0.4g Sucrose). Cells were washed 
twice again with lxPBS/l%FBS and then permeabilized with a permeabilization buffer 
for lOminutes (19ml lxPBS, 1ml 10% NP40, 2g Sucrose). Cells were washed twice with 
lxPBS/l%FBS then stained with primary antibody for rev or FLAG (Herc5) (1:1000) for 
1 hour. Cells were washed using the lxPBS/l%FBS 6 times over 15 minutes and stained 
with a secondary antibody for 1 hour (1:1000). Cells were washed again 6 times over 15 
minutes and then mounted on to slides using VECTASHIELD® hard set™ mounting 
medium with DAPI. Slides were then examined using a Zeiss LSM 510 META confocal 
microscope mounted on an inverted Axiovert 200 motorized microscope. For statistical 
analysis, 100 cells were counted for each different condition and were categorized 
according to their nuclear morphology (either lobed or not lobed) or the Rev localization 
(nucleolar, nuclear, nuclear boarder, cytoplasmic).
2.7 Propidium Iodide Staining for Cell Cycle analysis
U20S and 293T cells were transfected using FuGene® at 70% confluency. 
24hours after transfection, cell cycle control cells were treated with hydroxyurea (ImM) 
dissolved in water. 24 hours after drug treatment, cells were harvested with PBS/EDTA 
and washed twice with PBS. Cells were resuspended in 0.5ml of PBS (single cell 
suspension) and added to 4.5mls of ice cold 70% ethanol and kept on ice for 2 hours to
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allow for fixation. Cells were collected by centrifugation at 300xg for 5 minutes and 
ethanol was decanted. Cells were then washed and resuspended in PBS then collected by 
centrifugation at 200xg for 5 minutes. PBS was decanted and cells were suspended in 
0.5ml of propidium iodide staining solution (10ml 0.1%Triton X-100, 0.5mg DNase free 
RNaseA, 200ul of lmg/ml Propidium Iodide) and incubated at 37°C for 15 minutes.
Cells were then counted and analyzed using flow cytometry and interpreted using ModFit 
LT™.
2.8 Statistics
Statistical analysis was performed for experiment 2.5 - Growth analysis of Herc5 
transfected cells. Data was analyzed using a two-way ANOVA in the GraphPad Prism 5 
program, p values less than 0.05 were considered significant.
Chapter 3: Results
3.1 Generation of Herc5 mutants and RNA expression
Since the E3 ligase function (HECT domain) of Herc5 was shown to be unnecessary for 
Herc5 to restrict HIV-1 release, the characterization of both the spacer and RLD was 
necessary to understand the mechanism by which Herc5 was acting as a viral restriction 
factor. To understand the physiological relevance of the Herc5 spacer and RLD domains, 
the generation of domain deletions of both the RLD and Spacer regions was essential. 
Experiments performed with these mutant constructs of Herc5 would allow us to observe 
the relevance of each domain to Herc5’s function. To determine the importance of the 
RLD for Herc5 restriction of virus, truncations of the RLD were generated using PCR 
amplification. Forward primers recognizing each blade of the RLD created increasingly
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larger truncations of the domain when paired with a reverse primer recognizing the end of 
the coding region of Herc5 (Fig. x, Supplementary Table 1). A total of 7 deletions were 
made in this domain and were amplified using PCR (Supplementary Table 2). These 
deletions were subcloned into the pFLAG vector. Only Al, A1-3, and A1-7 RLD (ARLD) 
were successfully cloned into pFLAG based on sequencing analysis. Western blot of 
U20S cells transfected with the pFLAG RLD mutants was performed to test protein 
expression of the mutant constructs. Wild type CS2+ Herc5 was used a positive control 
and gave a product of 117kDa. A protein product of roughly 105kDa, 95kDa, and 80kDa 
was to be expected for successful detection/expression of 1, A1-3, and A1-7 RLD (ARLD) 
respectively. However, none of these mutant constructs were detectable (Fig. 1). MG 132 
(Sigma) and amantadine-hydrochloride (Sigma) were used to inhibit the proteasome and 
lysosome respectively to determine if the protein products were being degraded by either 
of these enzymes. However, no enhancement in expression of the RLD constructs was 
observed. The A1-2, A1-4, A1-5, A1-6 RLD pFLAG clones were also unable to be 
obtained. Since Al, Al -3, and ARLD pFLAG mutants were unable to express protein 
and A1-2, A1-4, A1-5, A1-6 RLD mutants were not easily cloned into the pFLAG 
backbone, RLD mutants were re-cloned in a CS2+ plasmid backbone. Primers were 
redesigned to generate the RLD mutants using modified site directed mutagenesis from 
the CS2+ WT Herc5 construct. Using modified site directed mutagenesis Al-2, Al-5, and 
A1-7RLD (ARLD) were successfully generated in the CS2+ plasmid backbone. Modified 
site directed mutagenesis was also used to generate the Aspacer mutation. All constructs 
were sequenced at Robarts Sequencing Facility and verified using GENtle bioinformatics 
software. U20S cells, which do not express Herc5 and therefore eliminated any potential
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Ubiquitin + + + .......................................................................
Herc5 . . .  + + + - - -  . . .  . . .
ARLD ............................... + + + . . .  . . .
A1RLD ....................................................+ + + - - -
A 1 - 3 R L D ......................................................................  + + +
DMSO + -  - + . . + . .  + . .  + . .
Mgl32 . + .  - + - . +  . . +  . . + .
Amantadine - - +  . .  + . .  + . . +  . . +
Herc5
Actin 42kDa
Fig. 1 Western blot for protein expression of pFLAG Herc5 RLD mutants in 
comparison to pCS2+ WT Herc5. Polyclonal Herc5 antibody (Abnova) was used to 
blot for Herc5 constructs. IOuM MG132 (Sigma) was used to inhibit the proteasome and 
0.5mM amantadine-HCl (Sigma) was used to inhibit the lysosome. DMSO was used as a 
control for both MG132 and amantadine effects. Ubiquitin was used as a negative 
control. Transfections were done using FuGene transfection reagent and harvested 24 
hours later. Data shown is representative of two independent trials (n=2).
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Fig. 2 RTPCR of CS2+ Herc5 constructs from U20S transfected cells. U20S cells 
were transfected with the Herc5 constructs as they are a natural knockdown of Herc5. 
Total mRNA was extracted 24 hours later and reverse transcribed into cDNA which was 
then PCR amplified using a forward primer beginning at the spacer region and reverse 
primer beginning at the end of the HECT domain. For the Aspacer mutant of Herc5, 
primers were used so that only the HECT domain was amplified. Al construct displayed 
in this 1 %DNA agarose gel is in the pFLAG backbone and is part of the first set of Herc5 
mutants cloned into the pFLAG backbone. The Herc5 constructs which display mRNA 
production were those cloned in the CS2+ plasmid backbone.
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for background Herc5 mRNA detection, were transfected with mutant constructs and RT 
PCR was performed to test expression of mRNA (Fig. 2). mRNA production was 
detectable for all CS2+ Herc5 mutant constructs.
3.2 Effect of Herc5 on cell viability and growth
Observations made in preliminary studies suggested that Herc5-transfected cells 
grew more slowly than non-Herc5 transfected cells (DMEM colour changed due to 
greater acidity in media from high confluency of pGL3 transfected and non-transfected 
cells). In addition, defects in nucleocytoplasmic shuttling of mRNA show retarded 
growth via restriction of cell cycle in the G2/M stage [131,133,134]. If Herc5 was 
affecting nucleocytoplasmic shuttling of HIV-1 mRNA, retarded growth would be 
expected in Herc5 transfected cells. To determine whether Herc5 was affecting 
replication of cells through this mechanism, growth curves were generated for WT Herc5 
and mutant construct transfected HeLa cells over a period of 4 days. Interestingly, Herc5 
transfected cells showed a much slower rate of replication in comparison to cells 
transfected with a promoterless plasmid (pGL3) (Fig. 3). Eliminating E3 ligase activity 
(C994A) and spacer region of Herc5 did not affect the ability of Herc5 to slow the cell 
cycle. However, cells transfected with the ARLD Herc5 constmct displayed a growth 
pattern comparable to that of the negative control. In addition, when any of the blades of 
the Herc5 RLD were deleted (A1-2RLD and A1-5RLD) the rate of growth was also 
comparable to ARLD transfected and pGL3 transfected cells (Fig. 3, Supplementary 
Table 3). This suggests that the RLD of Herc5 is important for the regulation of cell 
cycle progression and that even a small deletion of its structure will eliminate Herc5’s 
ability to restrict cell cycle. Additionally, this supports the hypothesis that the RLD may
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be affecting nucleocytoplasmic shuttling of mRNA by displaying a comparable 
phenotype. Cell viability tests were also performed on the Herc5 construct transfected 
cells in which both live and dead cells were counted for each construct. There was no 
significant difference in the viability of cells when compared across the mutant constructs 
(data not shown).
3.3 Propidium Iodide staining for cell cycle analysis
Defects in nucleocytoplasmic shuttling of mRNA results in retarded cell cycle, 
predominantly in the G2/M stage of cell cycle [131]. Section 3.2 demonstrated retarded 
cell cycle in Herc5 transfected cells; however the stage cell cycle restriction is not clear 
(if at all). To determine whether Herc5 generates an arrest of cell cycle and whether it is 
similar to the arrest seen in nucleocytoplasmic mRNA shuttling defective cells (at the 
G2/M stage of cell cycle), propidium iodide staining for DNA content of cells transfected 
with WT Herc5, C994A, spacer or RLD mutant constructs was performed and analyzed 
using flow cytometry. During interphase of the cell cycle, nuclear DNA content of cells 
duplicates to prepare for mitosis. By the end of G2, the end of interphase, cells contain 
twice as much DNA as in G l, the beginning of interphase. S phase which occurs 
between the two stages is the onset of DNA duplication and therefore contains more 
DNA than Gl but not as much DNA found in G2. The intensity of the PI stain correlates 


















-O- RLD mutant 
-e- RLD 1-2 
-a- RLD 1-5
Fig . 3 Growth comparison of Herc5 constructs in HeLa cells. Transfection of HeLa cells 
was performed using SuperFect transfection reagent. Experiment was performed in triplicate. 
The mean of three trials was plotted for each day for each construct. Growth rates of all 
construct transfected cells were compared to pGL3 negative control. Significant differences 
in growth were observed for WT, C994A, and ASpacer (p < 0.05) (n=3)
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Hydroxyurea, a drug which arrests cell cycle at G l, was used as a positive control for the 
detection of changes in cell cycle (Fig. 4, panel B). Cells were transfected using FuGene 
and harvested 48 hours later. Interestingly, 11.25% more Herc5 transfected HeLa cells 
were in G2 or M phase of the cell cycle than cells transfected with pGL3 (Fig. 4 panel, C 
and D). This growth characteristic was also observed in cells transfected with the C994A 
mutant meaning the E3 ligase activity of Herc5 is not required for the restricted growth 
seen in HeLa cells (Fig. 4, panel E). However, the ARLD mutant did not demonstrate a 
large proportion of cells in G2 and resembled cells which had been transfected with the 
pGL3 (Fig. 4 panel F). This further suggests that the RLD of Herc5 is necessary for the 
arrested growth seen in Herc5 transfected cells at the G2 phase or M phase of cell cycle.
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Fig. 4 Propidium Iodide staining for cell cycle analysis of HeLa cells transfected with Herc5 
constructs. Cells were transfected with FuGene transfection reagent and harvested 48 hours 
later. Cells were fixed for 2 hours in 70% ethanol before being stained with PI. A) untransfected 
cells were used as a negative control B) ImM Hydroxyurea was used to arrest cell cycle. C-F) 
Transfected cells. ModFit LT™ was used to analyse cell cycle. Manual analysis was needed for 
C994A and hydroxyurea data as peaks were not clearly discemable by the predictive software. 
The gates for these panels were modeled off gates used for Herc5. Experiment was carried out 
only once (n=l).
- 62 -
3.4 N u cle a r m orp h o lo gy
Unusual nuclear morphologies have been described for cells which are defective 
in nucleocytoplasmic shuttling of mRNA due to deficiencies in nuclear membrane 
assembly [135]. Since cell cycle analysis experiments of Herc5 transfected cells have 
shown similar growth characteristics to cells defective in nucleocytoplasmic shuttling of 
mRNA, the exploration of the nuclear morphology was logical. To observe the 
phenotype of Herc5 transfected cells and see if they displayed abnormal nuclear 
morphologies, immunofluorescence labelling of HeLa cells transfected with the various 
Herc5 constructs was performed and visualized using confocal microscopy. DAPI 
staining was used for nuclear staining. Interestingly, Herc5 transfected cells had 48% 
more C-shaped nuclei or nuclei which were lobed and appeared to be dividing into new 
cells than pGL3 transfected. This same morphology was seen for cells transfected with 
the C994A mutant of Herc5 (41.5% more than pGL3) as well as the Aspacer mutant (48% 
more than pGL3). This phenotype was eliminated when the ARLD Herc5 mutant was 
transfected. When any of the blades of the RLD were deleted (Al-2 or A1-5) the cells 
still displayed the phenotype representing pGL3 transfected cells which suggests that the 
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Fig. 5 Lobed nuclear morphology of Herc5 transfected cells. A) confocal microscopy 
performed on Herc5 construct transfected cells (lipofectamine transfection) Red=Flag 
tagged Herc5, DAPI/Blue= nucleus. White arrows highlight lobed nuclear morphology, 
red arrows indicate normal nuclear morphologies. B) percent of cells displaying lobed 
nuclear phenotypes. At least 100 cells were counted from each Herc5 construct. No 
statistical analysis could be performed on this data as the experiment was only carried out 
successfully one time (n=l).
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3.5 R e v  Lo c a liza tio n
Preliminary results showing a restriction of HIV-1 protein production but 
increased levels of mRNA suggested Herc5 may be impacting the ability of HIV-1 
mRNA to shuttle into the cytoplasm. Since the HIV-1 Rev protein is an accessory 
protein required for shuttling of HIV-1 mRNA into the cytoplasm it was logical to test 
whether Herc5 was impacting nucleocytoplasmic shuttling of HIV-1 mRNA by altering 
Rev activity. In the absence of vRNA, Rev is able to shuttle host mRNA into the 
cytoplasm, therefore this experiment was done without the use of replication competent 
HIV-1 and only with Rev to specifically examine the effects of Herc5 on its localization. 
If Herc5 has any effect on Rev’s ability to shuttle mRNA from the nucleus, it would still 
be detectable in the absence of other HIV-1 RNA. Alterations in Rev’s ability to shuttle 
HIV-1 mRNA into the cytoplasm would be accompanied by an observable change in 
localization of the rev protein - particularly an inability of Rev to shuttle to the cytoplasm 
and export cellular mRNA in the presence of Herc5. To assess the effect of Herc5 on 
Rev localization, HeLa cells were co-transfected with one of the various Herc5 constructs 
and the HIV RNA shuttling protein Rev at an 8:1 ratio. Cells were stained using an anti- 
Rev antibody and immunofluorescent anti- mouse secondary antibody. DAPI was used 
to stain the nucleus. Cells transfected with any of the Herc5 constructs or with 
promoterless vector (pGL3) did not display altered Rev localization. All Rev transfected 
cells showed Rev contained in the nucleolus of the nucleus where a large concentration of 
ribosomal RNA is known to be located and transcribed. Rev was not readily detectable 
in any other cellular compartment or in the cytoplasm (Fig. 6).
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Fig. 6 Rev Localization in HeLa cells transfected with Herc5 mutant constructs. Rev was
co-transfected with one of the Herc5 constructs. With each treatment, Rev was found only to 
localize in the nucleolus of cells. No other localization of Rev or other phenotypes were seen. 
Red= rev, DAPI/Blue= nucleus. Transfections were performed using lipofectamine (n=3)
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Chapter 4: Discussion
4.1 Summary and Interpretation of Data
In summary, our lab has identified a novel HIV restriction factor, Herc5 which 
may be able to restrict HIV release via two mechanisms: 1) the inhibition of virus release 
by its E3 ligase and ISGylation of gag, and 2) the inhibition of protein synthesis likely 
due to an inhibition of RNA trafficking to the cytoplasm for translation resulting in 
decelerated growth. We have shown that this second mechanism of HIV restriction is not 
due to Herc5’s E3 ligase function since mutating the key C994 residue to alanine, which 
is necessary for Herc5’s ligase activity, did not interfere with Herc5’s ability to restrict 
vims translation. Therefore, creation of Herc5 domain mutants was necessary for 
comprehending the mechanism by which Herc5 is able to restrict HIV at a pre- 
translational step. An HIV release assay performed by Matthew Woods (Woods, M„ et 
al., 2011; unpublished) using the RLD and spacer mutants demonstrated the RLD of 
Herc5 to be important for this second mechanism of restriction due to the inability of 
ARLD Herc5 to restrict vims production. Additionally, the same experiment 
demonstrated that the spacer domain of Herc5 was not necessary for Herc5 in restricting 
HIV-1 release. Based on this result as well as preliminary studies that showed increased 
levels of mRNA (that is not being translated into protein) in the presence of Herc5, we 
hypothesized that the RLD of Herc5 may be preventing the shuttling of mRNA in the 
cytoplasm. To test our hypothesis, growth curves of HeLa cells transfected with various 
domain mutants of Herc5 (including ARLD, Al-2 RLD, A1-5RLD) were performed. 
Growth curve experiments showed that while WT Herc5 showed restricted or retarded 
cell cycling, the ARLD Herc5 and bladed deletions (Al-2, A1-5 RLD) constructs were
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able to grow at a rate comparable to cells transfected with a promoterless (pGL3) vector. 
Propidium iodide staining for nuclear content to determine cell cycle stage demonstrated 
Herc5 constructs were predominately found in G2 or M phase, whereas the ARLD and 
bladed mutants did not demonstrate any altered cell growth pattern and were 
predominately found in G1 phase like in pGL3 transfected cells. Based on these results, 
we have shown that Herc5 is a mediator of cell cycle progression through the activity of 
its RLD. Additionally, the effects of Herc5 on nuclear morphology are eliminated with 
any of the RLD mutants which show an increasing reliance of Herc5 on the RLD for its 
activity.
To elucidate the mechanism and significance of the RLD it must be compared to 
its most similar homologue, RCC1. Structurally, the RLD is almost identical to the RCC1 
protein (Fig. v). As mentioned earlier, the RCC1 is a key regulator of mRNA export to 
the cytoplasm by acting as a GEF for the Ran GTPase, exchanging Ran-GDP for Ran- 
GTP. This causes a build up of Ran-GTP in the cytoplasm which generates a GTP 
energy gradient across the nuclear membrane by which mRNA shuttles across. 
Interestingly, experiments looking at Herc5 interacting proteins have identified Ran as a 
binding partner [132- supplementary data]. Due to the high degree of structural 
homology between the RCC1 and RLD of Herc5 and that Ran is thought to interact with 
Herc5 and RCC1, it may be possible that the RLD is interacting with Ran similarly to its 
homologue RCC1 and functioning as a GEF for Ran-GDP converting it into Ran-GTP. 
Although this has not been directly tested, it has been suggested that Herc5 may act as a 
GEF for small GTPases like Ran [215]. If this were to occur in the cytoplasm (where 
Herc5 is found), Herc5 GEF activity may be able to counteract the GTP energy gradient
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that normally exists across the nuclear membrane that is required for mRNA shuttling and 
inhibit or reduce the export of mRNA into the cytoplasm. In addition, cells which are 
unable to hydrolyze Ran-GTP in the cytoplasm and therefore do not have a defined GTP 
energy gradient across the nuclear membrane show an arrest at the G2/M stage of cell 
cycle similar to what we have seen in the presence of Herc5 [133,134], If the RLD of 
Herc5 is acting as a GEF for Ran-GDP, it is possible that its conversion into Ran-GTP in 
the cytoplasm outweighs the rate of hydrolyzing Ran-GTP leading to defective mRNA 
shuttling and cell cycle possibly an arrest at G2/ M phase. In the presence of ARLD 
Herc5 mutant, the G2/M cell cycle profile seen in WT Herc5 is abolished and resembles 
the pGL3 negative control. If the RLD of Herc5 is maintaining GEF activity for Ran, we 
would expect that the deletion of this domain would also display the same phenotype as 
we have observed in our ARLD cell cycle experiments, where ARLD Herc5 does not 
affect cell cycle. That is, deletion of the potential GEF acting domain, ARLD, would 
eliminate cytoplasmic Ran-GDP conversion to Ran-GTP by Herc5. Thus there would no 
longer be an equalization of Ran-GTP across the nuclear membrane caused by Herc5 
GEF activity and instead the cell would resume a normal build up of nuclear Ran-GTP 
which therefore would allow shuttling of mRNA to the cytoplasm. To further implicate 
the RLD in Herc5 cell cycle, the E3 ligase activity of Herc5 of Herc5 was necessary for 
the G2/M phenotype since deletion of these features did not affect the cells’ G2/M profile 
in PI staining experiments.
It was unfortunate that there were technical issues in the processing of the Aspacer 
and bladed mutants of the RLD for PI staining and cell cycle analysis. This data would 
have been valuable in determining whether or not the spacer domain showed the same
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G2/M phenotype and allow for greater confidence that the RLD is responsible for the 
G2/M phenotype. The bladed mutants would have also helped to determine whether the 
full RLD structure is necessary to observe the cell cycle mediating effects of Herc5.
Based on the cell viability and growth analysis experiment, my assumption would be that 
since the spacer domain maintained slowed growth and that cells transfected with the 
bladed mutants had normal growth rates, the spacer domain would not be necessary to 
observe the G2/M phenotype whereas either of the bladed mutations would have shown 
regular cell cycle progression. Processing issues such as these and fewer than 10,000 
cells analysed for certain samples during the PI staining experiment make it increasingly 
important for the experiment to be repeated at least twice more. The use of 10cm dishes 
would be more appropriate so that at least 20,000 cells could be collected from each 
sample and therefore claims of cell cycle arrest would be more statistically relevant. In 
addition, hydroxyurea treated cells were inhibited almost entirely in G1 and S phase 
therefore eliminating a second G2 peak. As a result, the ModFit software was not 
accurately able to model cell cycle peaks automatically for hydroxyurea treated cells. As 
well, C994A transfected cells displayed a large amount of background staining which 
also affected ModFit automatic prediction of peaks. Instead, these samples were assessed 
manually using the same gates used for the analysis of Herc5 cell cycle. Repetition 
would allow for statistical analysis to be carried out and greater confidence that the 
results observed are not artificial and reproducible.
RT PCR of Herc5 constructs was performed instead of protein detection using 
western blot due to an inconsistency for detection of Herc5 protein. Inconsistency in 
protein detection was not due to transfection since mRNA of Herc5 constructs was
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successfully reverse transcribed from U20S (natural Herc5 knockdowns with no basal 
production of Herc5). However, Herc5 construct proteins were detectable using confocal 
microscopy of transfected HeLa cells using the same antibody used for western blot (anti- 
FLAG). Although HeLa cells are not natural Herc5 knockdowns, the use of FLAG 
antibody instead of Herc5 antibody allows for detection of only transfected Herc5 
constructs. HeLa cells are also much more susceptible to taking up plasmid and therefore 
are higher expressers of transfected protein. It is possible that the ability to detect Herc5 
in confocal microscopy is due to the use of a different cell type rather than a change of 
detection method. It is also possible, however, that the change in detection ability is due 
to a change in secondary antibody that was used for confocal microscopy and not for 
western blot. It might be of greater value to perform nickel column pulldown of Herc5 
mutant construct transfected cell lysates. However, re-generation of the Herc5 mutants 
would need to be done so that they would express a HIS tag needed for the nickel column 
assay. Performing this assay would allow for greater ability to assess stability of the 
protein and should be done in parallel with drugs inhibiting proteasomal (MG 132) and 
lysosomal (amantadine) degradation to ensure they are not being prematurely degraded.
Although it is clear that Herc5 transfected cells have altered cell cycle, growth, 
and are predominately in G2/M stage of cell cycle, it cannot be determined whether the 
altered growth of Herc5 transfected cells is due to an irreversible arrest of cell cycle at 
G2/M or a prolongation of G2/M phase based on the experiments performed. Studies that 
have previously investigated the effects of defective mRNA shuttling to the cytoplasm 
suggest that cell cycle is restricted rather than prolonged [131,133]. Deursen et al, 
showed that defects in the CAN protein, which is necessary for nuclear pore formation
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and shuttling of mRNA out of the nucleus, causes an arrest of cell cycle predominately in 
G2 stage. Additionally, Ren et al showed a restriction of cell cycle at G2 when there was 
accumulation of mRNA in the nucleus and impaired GTP hydrolysis in the cytoplasm. If 
Herc5 is affecting shuttling of mRNA into the cytoplasm, it is possible that the G2 cell 
cycle phenotype is due to cell cycle arresting rather than prolongation. However, it has 
also been noted that increases in the cytoplasmic Ran-GTP binding protein RanBPl, 
which acts as a co-factor for the Ran-GTP hydrolyzing protein RanGAPl, lead to 
prolonged mitosis in mammalian cells [136]. Increases in Ran-GTP in the cytoplasm due 
to Herc5 may cause an upregulation of RanBPl and affect cell cycle in this manner which 
might suggest Herc5 is resulting in slower growth of cells rather than restriction in cell 
cycle. In experiment 3.2, growth analysis was performed on Herc5 and mutant construct 
transfected cells. Although WT Herc5, C994A, and Aspacer transfected cells all 
displayed slower rates of growth, these cells all continued to grow until they reached 100% 
confluency. This would suggest that growth of these cells was only slowed rather than 
restricted, however, since transfection rate is not 100% it cannot be ruled out that cells 
transfected with Herc5 were restricted in growth while untransfected cells in the well 
continued to grow until the well reached confluency. An important observation that was 
observed in the Deursen et al study was a normal nuclear envelope assembly of G2 
arrested cells. Since we observed abnormal nuclear morphologies in the presence of 
Herc5 it is possible that cell cycle restriction at G2/M is less likely.
The nuclear morphology experiment shows that the abnormal cell cycling of 
Herc5 transfected cells is accompanied with a c-shaped or multi-lobed nuclear phenotype. 
This phenotype can also be supported by a defunct Ran-GTP gradient across the nuclear
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membrane. It has been shown in Xenopus egg extracts that increased cytoplasmic Ran- 
GTP disrupts proper assembly of the nuclear envelope leading to abnormally small 
nuclear morphologies albeit not the same morphologies as we have seen in HeLa cells 
[224]; however this may be due to cell line variability. Particularly, Ran-GDP in the 
cytoplasm is necessary for proper nuclear envelope fusion in the process of nuclear 
assembly [136]. If the Herc5 RLD is contributing to an increased cytoplasmic Ran-GTP 
concentration by acting as a GEF for Ran, it may lead to the abnormal nuclear 
morphologies we have observed in HeLa cells transfected with WT Herc5. Herc5 
lacking E3 ligase function (C994A) and ASpacer Herc5 also display abnormal nuclear 
morphologies as shown in Figure 5 further implicating the importance of the RLD in this 
Herc5 phenotype and suggesting that mRNA shuttling defect, cell cycle irregularity, and 
nuclear morphology abnormality are all due to RLD activity. Interestingly, the use of any 
of the bladed RLD mutants showed morphology phenotypes that were comparable to 
pGL3 transfected cells, which strongly suggests the importance of the entire domain in 
Herc5’s cell cycle activity and impact on nuclear morphology. However, this experiment 
must be repeated at least two more times since it was only performed once successfully 
and thus no statistical significance can be claimed.
In an HIV-1 release assay using pGL3, WT Herc5, C994A, ASpacer, and ARLD 
mutants, the ASpacer and C994A Herc5 constructs show equal if not more potent effects 
in comparison to the WT Herc5 (data not shown) (Woods, M., et al 2011; unpublished). 
Additionally, although nuclear morphology experiments show a similar propensity for 
lobed nuclei to occur in WT transfected cells as C994A or ASpacer constructs, both 
C994A and ASpacer mutants show a more pronounced abnormal lobed phenotype. These
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observations may be explained by the hypothesis that Herc5 might autoregulate itself 
through ISGylation of its spacer domain to subsequently shutdown the protein function. 
Therefore, eliminating the E3 ligase activity of Herc5 by C994A point mutation or 
deletion of the spacer domain could be increasing Herc5 stability, prolonging its activity 
and subsequently enhancing its effects by preventing/slowing turnover. Western blots 
performed on Herc5 construct stability show that of all Herc5 modified site directed 
mutagenesis generated constructs, the Aspacer mutant is most stable (data not shown). It 
would be important to do a stability trial for the C994A mutant as well to see if the 
protein is as stable as the Aspacer construct. The other well known ISG15 conjugating 
E3 ligase, EFP, also contains a domain in which multiple alpha helices reside similar to 
the spacer region of Herc5. AutoISGylation of this domain by EFP leads to negative 
regulation of its expression and protein turnover [139]. Future experiments should 
include immunoprécipitation of all Herc5 constructs from transfected cell lysates to 
compare the levels of intracellular protein. Although immunoprécipitation is only semi- 
quantitative, large differences in protein expression would be considered significant. If 
this hypothesis is correct it may help to explain some unusual results seen in the PI 
staining experiment. Particularly, large amounts of background staining seen for C994A 
transfected cells which affected ModFit ability to automatically predict peaks for G l, S, 
and G2. It is possible that the wide peaks for the C994A mutant were due to an 
incomplete digestion of RNA in cells. Although all cells were treated with RNaseA for 
an equal amount of time (20 minutes), cells transfected with Herc5 and C994A may have 
increased levels of RNA in the nucleus if our hypothesis that the RLD domain is 
restricting trafficking of RNA into the cytoplasm is correct. In addition, C994A may
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have even greater amount of RNA build up than Herc5 if the construct is in fact more 
stable than wild type Herc5. It would be interesting if this wide peak phenomenon was 
also seen in cells transfected with ASpacer Herc5, again since this construct may be more 
stable and therefore have exaggerated and prolonged effects on cell cycle.
Immunofluorescence of Rev in HeLa cells co-transfected with Herc5 constructs 
demonstrated that no differences in Rev localization could be detected between any 
samples. Perhaps due to high the concentration of mRNA that is located in the nucleolus, 
Rev predominately localizes here and only few Rev molecules are necessary to shuttle 
RNA to cytoplasm. If such is the case, immunofluorescence may not be sensitive enough 
to detect cytoplasmic Rev or changes in levels of Rev in the cytoplasm. It should be 
expected that in pGL3 transfected cells, Rev would be detectable in both the nucleus and 
cytoplasm. However, if in the negative control Rev is undetectable in the cytoplasm by 
confocal microscopy, defects in Rev ability to shuttle mRNA into the cytoplasm in the 
presence of Herc5, as we would expect, would also be undetectable. It is important to 
find another assay to establish whether or not Herc5 is affecting Rev shuttling in order to 
determine the mechanism by which Herc5 affects HIV-1 protein production. If Herc5 is 
able to act as a GEF for Ran in the cytoplasm and offset the GTP gradient across the 
nuclear membrane, then it would be expected that Rev, which uses the same GTP energy 
gradient to shuttle HIV-1 mRNA into the cytoplasm, would also be affected and perhaps 




4.21 Quantification o f cytoplasmic Rev in the presence ofHerc5 vs pGL3 and 
ARLD transfected cells
Future directions should include an assay that assesses the amount of cytoplasmic 
rev in the presence of Herc5 vs. ARLD Herc5 and pGL3. This would allow us to 
examine the affect of the RLD of Herc5 on Rev shuttling into and out of the nucleus and 
further suggest that Herc5 may be affecting the GTP gradient that is required for Rev to 
shuttle mRNA out of the nucleus. For quantitative analysis of cytoplasmic and nuclear 
Rev, separation of the two cellular compartments would have to be performed in order to 
determine their Rev concentrations individually. The ProteoJET™ cytoplasmic and 
nuclear protein extraction kit could be used for the separation of the cytoplasmic and 
nuclear fractions of cells transfected with the different Herc5 constructs. Lysates from 
both the cytoplasmic fraction and nuclear fractions could be run separately on an SDS 
page gel and blotted for rev contents. Cytoplasmic fractions can be quantitatively 
compared across samples to determine if there is a difference in rev levels when co­
transfected with Herc5 vs. pGL3 (promoterless vector -  negative control).
4.22 gRTPCR o f HIV mRNA in cytoplasm and nuclear fractions to evaluate 
shuttling ability in the presence ofHerc5 and mutant constructs
qRTPCR could be done for HIV protein mRNA in the cytoplasm and nucleus to 
determine any differences in mRNA shuttling/distribution that may exist between Herc5 
ARLD and wild type Herc5 transfected cells. This data would complement the Rev 
localization data mentioned above. Increased levels of HIV mRNA that are found with
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wild type Herc5 may be abolished in the presence of ARLD Herc5, which would suggest 
that this domain is required to restrict the shuttling of HIV mRNA. For example, 
ultracentrifugation (as an alternative to the ProteoJET™ cytoplasmic and nuclear protein 
extraction kit) of these cells would be performed to separate nuclear and cytoplasmic 
fractions. mRNA could be isolated from these fractions and digested to remove DNA. 
mRNA would then be reverse transcribed into cDNA and could be amplified by PCR 
with specific primers for HIV protein sequences such as gag forward and reverse primers. 
This would allow us to quantitatively measure the differences between cytoplasmic and 
nuclear mRNA in the presence of the Herc5 mutant constructs vs. the wild type and 
negative control. Again, if the ARLD mutant of Herc5 shows similar distribution of 
mRNA in the cytoplasm and nucleus as the negative control, it would further implicate 
the RLD in regulating cytoplasmic export of mRNA perhaps through GEF activity.
4.23 Quantification o f cytoplasmic Ran-GTP in the presence o f Here 5 vs. pGL3
nesative control and mutant constructs
To determine if Herc5 has an effect on cytoplasmic Ran-GTP levels, a Ran 
activation assay kit can be used (Cell Biolabs). This kit uses RanBPl (a Ran-GTP 
hydrolyzing enzyme that specifically recognizes GTP bound Ran) agarose beads to 
selectively pull down activated Ran from cell lysates. Herc5 and mutant construct 
transfected cells would be harvested and separated of cytoplasmic and nuclear contents 
through the previously described methodologies. The Ran activation assay kit could be 
used on the cytoplasmic fraction to quantitatively determine the concentration of Ran- 
GTP found in the cytoplasm. Cytoplasmic Ran-GTP would be compared in cells
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transfected with pGL3, WT and mutant (specifically ARLD Herc5) by immunoblotting 
for Ran.
4.24 Generation ofRLD active site mutants to evaluate the impact on Herc5 GEF 
activity (if any), mRNA shuttling capacity, nuclear morphology, cell cycle 
progression, growth curve, and rev localization.
Currently we have designed three mutants of Herc5 which contain point mutations within 
the RLD. We wanted to test the importance of these residues since the homologous sites 
in RCC1 serve as active sites for RCC1 GEF activity towards Ran [220]. Reduced 
competency in Herc5 to restrict HIV or mRNA shuttling into the cytoplasm with one or 
all of these mutations would allow us to further characterize the importance of this 
domain for HIV restriction. These RLD point mutants should be compared to the ARLD 
mutant and the wild type Herc5 construct in the aforementioned experiments to determine 
if they completely abolish GEF activity (if any), mRNA shuttling of Herc5, and restrict 
cell cycle. If so, not only would we have strongly implicated the RLD as a GEF for Ran 
but also determined key active site residues of Herc5 that are necessary for HIV-1 
restriction.
4.25 Generation o f an RLD only construct lacking spacer and HECT domains o f 
Herc5
Primers have already been made to amplify the RLD region of Herc5 in the 
absence of the other domains. It would be interesting to see if this region alone would be 
able to counteract the Ran-GTP gradient across the nucleus by still acting as a GEF for 
Ran (if possible) and thus restrict HIV protein production. This would allow us to further
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understand the significance of this domain and possibly suggest evolutionary origins of 
Herc5. Should the domain be able to maintain its GEF activity (if any) and be able to 
restrict mRNA shuttling, it might suggest that the domain was once a singular protein and 
either further evolved to contain a spacer and RLD domain perhaps by associating with 
an ancient ISG15 E3 ligase to acquire stronger antiviral activity.
4.26 Generation o f point mutants at lysine residues in the spacer domain to
determine ifautoISGvlation in this domain leads to Herc5 turnover.
To determine the significance of the increased stability seen with the Aspacer 
Herc5 construct, point mutations of the lysine residues (where ISGylation occurs [218]) 
of the spacer domain should be made. Since the other ISG15 E3 ligase, EFP, contains a 
coiled coil domain that is structurally similar to the spacer domain of Herc5 and is 
autoISGylated to influence protein degradation, it would be interesting to see if the spacer 
domain of Herc5 has the same activity. Firstly, stability trials of wild type Herc5 
transfected cells in the presence of a deubiquitinating enzyme such as Ubp2 should be 
performed to determine if protein turnover is due to ubiquitination. Provided that 
deubiquitination of Herc5 does not increase protein stability, stability trials of wild type 
Herc5 should be performed in the presence of the de-ISGylating enzyme, Ubp43 and 
compared to the C994A Herc5 mutant (lacking ISG15 conjugative activity) and wild type 
Herc5 alone. An increase in stability of the Herc5 construct in the presence of Ubp43 
compared to wild type Herc5 and similar to C994A Herc5 stability would suggest that 
autoISGylation of Herc5 is causing turnover. Next, the spacer domain lysine residue 
point mutants should be transfected into cells and analyzed for stability and compared to 
wild type Herc5 stability. This would allow us to determine which residues are necessary
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for Herc5 turnover most likely due to ISGylation. To further assess if this is a site for 
ISG15 binding, wild type Herc5, Aspacer Herc5, and the lysine residue mutated spacer 
domain of Herc5 should be transfected into cells in the presence of ISG15 and then 
immunoprecipitated in the presence of Herc5 (or flag) antibody. The bound product can 
then be run on a non-denaturing SDS page gel and blotted for ISG15 to determine the 
capacity of each construct to be modified with ISG15. An inability of ISG15 to bind to 
Aspacer and ability to bind to wild type Herc5 would definitively prove the region is 
ISGylated. With the individual lysine residue point mutants in the spacer domain of 
Herc5, we can also determine the exact lysines which are targets for autoISGylation. 
Completion of these experiments would elucidate some of the functional properties of the 
spacer domain of Herc5.
4.27 Evolutionary comparison ofHerc5 across various primate species.
In the future, it would also be very interesting to determine the evolutionary conservation 
of Herc5 amongst primates. Since Herc5 is found in only primates, Herc5 from different 
primate cell lines can be reverse transcribed using human Herc5 primers- initially. 
Although these human primers may not be able to amplify Herc5 proteins that exist in 
other primate species due to sequence variability, some primate species that are 
sequentially identical or highly similar may yield a Herc5 protein sequence. If not, Herc5 
sequences of Rhesus macaques, northern white faced gibbons, Sumatran orangutans, 
marmosets, and chimpanzees from any of which Herc5 primers can be made. These 
primers would begin in the non-coding regions of Herc5 so that the coding region of the 
primate Herc5 sequence would be intact and not contain nucleotide differences that may 
be present if using human coding region Herc5 primers. These evolutionary comparisons
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of proteins across species have been performed for other HIV restriction factors such as 
TRIM22 and TRIM5a. These studies show that the prevalence of TRIM22 and TRIM5a 
within mammalian species is highly selective favouring one protein or the other. 
Specifically, the selection of TRIM22 over TRIM5a in new world monkeys and humans 
has occurred over the last 23 million years possibly reflecting a change in pathogenic 
environment [217]. Herc5 isolated from various primate cell lines could be tested on 
their ability to restrict HIV (or SIV) to assess their antiviral activity and possibly allow us 
to observe when in evolutionary history Herc5 acquired antiviral activity-particularly by 
comparing Herc5 antiviral activity in old world and new world monkey cell lines.
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Supplementary Figures
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Supplementary Figure 2. pCS2+ plasmid map. Original WT Herc5 construct was 
cloned in this backbone.
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Supplementary Table 1- Primers used for generation of pFLAG Herc5 RLD mutants.
Mutant Forward primer 5’ -> 3’
A1 RLD ACG TAG ATC TAG TAG 
GGT GGA GGT GAC GC
Al-2 RLD ACG TAG ATC TAG TCA 
AGG AGC AGA GCA CAT 
GC
Al-3 RLD ACG TAG ATC TAT GGG 
TGG TGA GCT TTT TGC 
CTGG
Al-4 RLD ACG TAG ATC TAT GTC 
CAT GTC TGG CAA CAT 
TTA TTC ATG G
A1-5 RLD ACG TAG ATC TAT GGA 
TGG GCT GCT GTT TAC 
TTTCGG
A1-6 RLD ACG TAG ATC TAT GGG 
AAA GGT CTT TTC CTT 
TGG TTC TGG
A1-7 RLD (all RLD) ACG TAG ATC TAT GAT 
GAT TGC TGG AGG GAA 
TCA AAG C
Herc5 coding region reverse 
primer
ACG TTC TAG ATC AGC 
CAA ATC CTC TG
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Supplementary Table 2. PCR conditions for amplification of pFLAG Herc5 RLD 
constructs
A.











Temperature Time # of cycles
Initial Denature 95 °C 3 minutes lx
Denature 95°C 30 seconds 32x
Annealing 50.5°C 30 seconds 32x
Extension 72°C 4 minutes 32x
Final Extension 72°C 10 minutes lx
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Supplementary Table 3. Statistical analysis of cell cycle growth curve generated using two- 
way ANOVA in GraphPad Prism 5.
Two-way RM ANOVA Matching by cols
Source of Variation % of total variation P value
Interaction 4.71 0.0004
Day 82.83 < 0.0001
Treatment 7.97 < 0.0001
Subjects (matching) 0.8137 0.5766




Subjects (matching) ns No
Source of Variation DfSum-of-squares Mean square F
Interaction 24 1.475e+011 6.145e+009 2.994
Day 4 2.594e+012 6.486e+011 316.0
Treatment 6 2.497e+011 4.162e+010 22.86
Subjects (matching) 14 2.548e+010 1.820e+009 0.8869
Residual 56 1.149e+011 2.052e+009
Number of missing values 0
Bonferroni multiple Number of
comparisons comparisons: 30
pGL3 vs WT 
Treatment pGL3 WT Difference 95% Cl of diff.
Day 1 36000 43000 7000 -112607 to 126607
Day 2 127000 59000 -68000 -187607 to 51607
Day 3 283333 146667 -136667 -256273 to -17060
Day 4 410000 196667 -213333 -332940 to -93727
Treatment Difference t P value Summary
Day 1 7000 0.1914 P > 0.05 ns
Day 2 -68000 1.859 P > 0.05 ns
Day 3 -136667 3.737 P < 0.05
Day 4 -213333 5.834 P < 0.0001 ****
pGL3 vs C994A 
Treatment pGL3 C994A Difference 95% Cl of diff.
Day 1 36000 43000 7000 -112607 to 126607
Day 2 127000 59000 -68000 -187607 to 51607
Day 3 283333 153333 -130000 -249607 to -10393
Day 4 410000 243333 -166667 -286273 to -47060
-87-
Treatment Difference t P value Summary
Day 1 7000 0.1914 P > 0.05 ns
Day 2 -68000 1.859 P > 0.05 ns
Day 3 -130000 3.555 P < 0.05 *
Day 4 -166667 4.558 P < 0.001 ***
pGL3 vs Spacer mutant
Treatment pGL3 Spacer mutant Difference 95% Cl of diff.
Day 1 36000 59000 23000 -96607 to 142607
Day 2 127000 79000 -48000 -167607 to 71607
Day 3 283333 256667 -26667 -146273 to 92940
Day 4 410000 190000 -220000-■ 339607 to -100393
Treatment Difference t P value Summary
Day 1 23000 0.6289 P > 0.05 ns
Day 2 -48000 1.313 P > 0.05 ns
Day 3 -26667 0.7292 P > 0.05 ns
Day 4 -220000 6.016 P < 0.0001 ****
pGL3 vs RLD mutant
Treatment pGL3 RLD mutant Difference 95% Cl of diff.
Day 1 36000 76000 40000 -79607 to 159607
Day 2 127000 130000 3000 -116607 to 122607
Day 3 283333 330000 46667 -72940 to 166273
Day 4 410000 410000 0.0 -119607 to 119607
Treatment Difference t P value Summary
Day 1 40000 1.094 P > 0.05 ns
Day 2 3000 0.08204 P > 0.05 ns
Day 3 46667 1.276 P > 0.05 ns
Day 4 0.0 0.0 P > 0.05 ns
pGL3 vs RLD 1-2
Treatment pGL3 RLD 1-2 Difference 95% Cl of diff.
Day 1 36000 71000 35000 -84607 to 154607
Day 2 127000 158000 31000 -88607 to 150607
Day 3 283333 346667 63333 -56273 to 182940
Day 4 410000 346667 -63333 -182940 to 56273
Treatment Difference t P value Summary
Day 1 35000 0.9571 P > 0.05 ns
Day 2 31000 0.8477 P > 0.05 ns
Day 3 63333 1.732 P > 0.05 ns
Day 4 -63333 1.732 P > 0.05 ns
pGL3 vs RLD 1-5
Treatment pGL3 RLD 1-5 Difference 95% Cl of diff.
Day 1 36000 63000 27000 -92607 to 146607
Day 2 127000 132000 5000 -114607 to 124607
Day 3 283333 350000 66667 -52940 to 186273
-88-
Day 4 410000 413333 3333 -116273 to 122940
Treatment Difference t P value Summary
Day 1 27000 0.7383 P > 0.05 ns
Day 2 5000 0.1367 P > 0.05 ns
Day 3 66667 1.823 P > 0.05 ns
Day 4 3333 0.09115 P > 0.05 ns
-89-
References
1. Pickart, C. M. & Eddins, M. J. Ubiquitin: structures, functions, mechanisms. Biochim. 
Biophys. Acta 1695, 55-72 (2004).
2. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503- 
533 (2001).
3. Di Fiore, P. P., Polo, S. & Hofmann, K. When ubiquitin meets ubiquitin receptors: a 
signalling connection. Nat. Rev. Mol. Cell Biol. 4, 491-497 (2003).
4. Hofmann, K. & Falquet, L. A ubiquitin-interacting motif conserved in components of 
the proteasomal and lysosomal protein degradation systems. Trends Biochem. Sci. 26, 
347-350 (2001).
5. Donaldson, K. M„ Yin, H., Gekakis, N., Supek, F. & Joazeiro, C. A. Ubiquitin signals 
protein trafficking via interaction with a novel ubiquitin binding domain in the membrane 
fusion regulator, Vps9p. Curr. Biol. 13, 258-262 (2003).
6. Shih, S. C. et al. A ubiquitin-binding motif required for intramolecular 
monoubiquitylation, the CUE domain. EMBO J. 22, 1273-1281 (2003).
7. Scheffner, M., Huibregtse, J. M„ Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and 
E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 
7 5 ,495-505 (1993).
8. Hatakeyama, S., Jensen, J. P. & Weissman, A. M. Subcellular localization and 
ubiquitin-conjugating enzyme (E2) interactions of mammalian HECT family ubiquitin 
protein ligases. J. Biol. Chem. 2 7 2 ,15085-15092 (1997).
9. Huibregtse, J. M., Scheffner, M„ Beaudenon, S. & Howley, P. M. A family of proteins 
structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc. Natl. 
Acad. Sci. U. S. A. 92, 5249 (1995).
10. Scheffner, M. & Staub, O. HECT E3s and human disease. BMC Biochem. 8 Suppl 1, 
S6 (2007).
11. Scheffner, M., Nuber, U. & Huibregtse, J. M. Protein ubiquitination involving an E l- 
E2-E3 enzyme ubiquitin thioester cascade. Nature 373, 81-83 (1995).
12. Schwarz, S. E., Rosa, J. L. & Scheffner, M. Characterization of human hect domain 
family members and their interaction with UbcH5 and UbcH7. J. Biol. Chem. 273, 
12148-12154(1998).
13. Garcia-Gonzalo, F. R. & Rosa, J. L. The HERC proteins: functional and evolutionary 
insights. Cell Mol. Life Sci. 62, 1826-1838 (2005).
-90-
14. Shearwin-Whyatt, L., Dalton, H. E„ Foot, N. & Kumar, S. Regulation of functional 
diversity within the Nedd4 family by accessory and adaptor proteins. Bioessays 28, 617- 
628 (2006).
15. Ingham, R. J„ Gish, G. & Pawson, T. The Nedd4 family of E3 ubiquitin ligases: 
functional diversity within a common modular architecture. Oncogene 23, 1972-1984
(2004).
16. Huang, L. et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination 
by the E2-E3 enzyme cascade. Science 286, 1321-1326 (1999).
17. Verdecia, M. A. et al. Conformational flexibility underlies ubiquitin ligation mediated 
by the WWP1 HECT domain E3 ligase. Mol. Cell 11, 249-259 (2003).
18. Wang, M. & Pickart, C. M. Different HECT domain ubiquitin ligases employ distinct 
mechanisms of polyubiquitin chain synthesis. EMBO J. 24, 4324-4333 (2005).
19. Kim, H. T. et al. Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin- 
protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all 
possible isopeptide linkages. J. Biol. Chem. 282, 17375-17386 (2007).
20. Scialpi, F. et al. Itch self-polyubiquitylation occurs through lysine-63 linkages. 
Biochem. Pharmacol. 76, 1515-1521 (2008).
21. Lim, K. L. & Lim, G. G. K63-linked ubiquitination and neurodegeneration. Neurobiol. 
Dis. 43, 9-16(2011).
22. Kim, H. C. & Huibregtse, J. M. Polyubiquitination by HECT E3s and the 
determinants of chain type specificity. Mol. Cell. Biol. 29, 3307-3318 (2009).
23. Hengstermann, A. et al. Growth suppression induced by downregulation of E6-AP 
expression in human papillomavirus-positive cancer cell lines depends on p53. J. Virol.
79, 9296-9300 (2005).
24. Lu, C., Pribanic, S., Debonneville, A., Jiang, C. & Rotin, D. The PY motif of ENaC, 
mutated in Liddle syndrome, regulates channel internalization, sorting and mobilization 
from subapical pool. Traffic 8, 1246-1264 (2007).
25. Zhou, R., Patel, S. V. & Snyder, P. M. Nedd4-2 catalyzes ubiquitination and 
degradation of cell surface ENaC. J. Biol. Chem. 282, 20207-20212 (2007).
26. Hannoun, Z., Greenhough, S., Jaffray, E., Hay, R. T. & Hay, D. C. Post-translational 
modification by SUMO. Toxicology 278, 288-293 (2010).
27. Vertegaal, A. C. et al. Distinct and overlapping sets of SUMO-1 and SUMO-2 target 
proteins revealed by quantitative proteomics. Mol. Cell. Proteomics 5, 2298-2310 (2006).
- 9 1 -
28. Rodriguez, M. S., Dargemont, C. & Hay, R. T. SUMO-1 conjugation in vivo requires 
both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276, 12654- 
12659 (2001).
29. Hay, R. T. Role of ubiquitin-like proteins in transcriptional regulation. Ernst Schering 
Res. Found. Workshop (57), 173-192 (2006).
30. Sharrocks, A. D. PIAS proteins and transcriptional regulation—more than just SUMO 
E3 ligases? Genes Dev. 20, 754-758 (2006).
31. Desterro, J. M. et al. SUMO-1 modification alters ADAR1 editing activity. Mol. Biol. 
Cell 16,5115-5126 (2005).
32. Zhao, J. Sumoylation regulates diverse biological processes. Cell Mol. Life Sci. 64, 
3017-3033 (2007).
33. Hartner, J. C., Walkley, C. R., Lu, J. & Orkin, S. H. ADAR1 is essential for the 
maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 10, 
109-115(2009).
34. Wang, Y. & Samuel, C. E. Adenosine deaminase ADAR1 increases gene expression 
at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha 
phosphorylation. J. Mol. Biol. 393, 777-787 (2009).
35. Lin, X., Liang, M„ Liang, Y. Y., Brunicardi, F. C. & Feng, X. H. SUMO-l/Ubc9 
promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J. 
Biol. Chem. 278, 31043-31048 (2003).
36. Roysland, K. et al. Analyzing direct and indirect effects of treatment using dynamic 
path analysis applied to data from the Swiss HIV Cohort Study. Stat. Med. (2011).
37. Steffan, J. S. et al. SUMO modification of Huntingtin and Huntington's disease 
pathology. Science 304, 100-104 (2004).
38. Cai, Q. & Robertson, E. S. Ubiquitin/SUMO modification regulates VHL protein 
stability and nucleocytoplasmic localization. PLoS One 5, el2636 (2010).
39. Atkins, D. J. et al. Concomitant deregulation of HIF1 alpha and cell cycle proteins in 
VHL-mutated renal cell carcinomas. Virchows Arch. 447, 634-642 (2005).
40. Shiio, Y. & Eisenman, R. N. Histone sumoylation is associated with transcriptional 
repression. Proc. Natl. Acad. Sci. U. S. A. 100, 13225-13230 (2003).
41. Kochs, G., Garcia-Sastre, A. & Martinez-Sobrido, L. Multiple anti-interferon actions 
of the influenza A vims NS1 protein. J. Virol. 81, 7011-7021 (2007).
-92-
42. Mibayashi, M. et al. Inhibition of retinoic acid-inducible gene I-mediated induction of 
beta interferon by the NS1 protein of influenza A virus. J. Virol. 81, 514-524 (2007).
43. Satterly, N. et al. Influenza virus targets the mRNA export machinery and the nuclear 
pore complex. Proc. Natl. Acad. Sci. U. S. A. 104, 1853-1858 (2007).
44. Xu, K. et al. Modification of nonstructural protein 1 of influenza A virus by SUMOl. 
J. Virol. 85, 1086-1098 (2011).
45. Mi, Z., Fu, J., Xiong, Y. & Tang, H. SUMOylation of RIG-I positively regulates the 
type I interferon signaling. Protein Cell. 1, 275-283 (2010).
46. Gong, L. & Yeh, E. T. Identification of the activating and conjugating enzymes of the 
NEDD8 conjugation pathway. J. Biol. Chem. 274, 12036-12042 (1999).
47. Xirodimas, D. P. Novel substrates and functions for the ubiquitin-like molecule 
NEDD8. Biochem. Soc. Trans. 36, 802-806 (2008).
48. Nakayama, K. I. & Nakayama, K. Regulation of the cell cycle by SCF-type ubiquitin 
ligases. Semin. Cell Dev. Biol. 16, 323-333 (2005).
49. Kawakami, T. et al. NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J. 20, 
4003-4012 (2001).
50. Edgar, B. A. & Orr-Weaver, T. L. Endoreplication cell cycles: more for less. Cell 105, 
297-306 (2001).
51. Tateishi, K„ Omata, M„ Tanaka, K. & Chiba, T. The NEDD8 system is essential for 
cell cycle progression and morphogenetic pathway in mice. J. Cell Biol. 155, 571-579 
(2001).
52. Baroth, M., Orlich, M., Thiel, H. J. & Becher, P. Insertion of cellular NEDD8 coding 
sequences in a pestivirus. Virology 278,456-466 (2000).
53. Gu, B. et al. The RNA helicase and nucleotide triphosphatase activities of the bovine 
viral diarrhea virus NS3 protein are essential for viral replication. J. Virol. 74, 1794-1800 
(2000).
54. Narasimhan, J. et al. Crystal structure of the interferon-induced ubiquitin-like protein 
ISG15. J. Biol. Chem. 280, 27356-27365 (2005).
55. Chang, Y. G. et al. Different roles for two ubiquitin-like domains of ISG15 in protein 
modification. J. Biol. Chem. 283, 13370-13377 (2008).
-93-
56. Malakhov, M. P. et al. High-throughput immunoblotting. Ubiquitiin-like protein 
ISG15 modifies key regulators of signal transduction. J. Biol. Chem. 278, 16608-16613 
(2003).
57. Malakhova, O. A. et al. Protein ISGylation modulates the JAK-STAT signaling 
pathway. Genes Dev. 17,455-460 (2003).
58. Jeon, Y. J., Yoo, H. M. & Chung, C. H. ISG15 and immune diseases. Biochim. 
Biophys. Acta 1802, 485-496 (2010).
59. Feng, Q. et al. UBE1L causes lung cancer growth suppression by targeting cyclin Dl. 
Mol. Cancer. Ther. 7, 3780-3788 (2008).
60. Desai, S. D. et al. Elevated expression of ISG15 in tumor cells interferes with the 
ubiquitin/26S proteasome pathway. Cancer Res. 66, 921-928 (2006).
61. D'Cunha, J. et al. In vitro and in vivo secretion of human ISG15, an IFN-induced 
immunomodulatory cytokine. J. Immunol. 157, 4100-4108 (1996).
62. Durfee, L. A., Lyon, N., Seo, K. & Huibregtse, J. M. The ISG15 conjugation system 
broadly targets newly synthesized proteins: implications for the antiviral function of 
ISG15. Mol. Cell 3 8 ,722-732 (2010).
63. Zhao, C., Hsiang, T. Y., Kuo, R. L. & Krug, R. M. ISG15 conjugation system targets 
the viral NS1 protein in influenza A virus-infected cells. Proc. Natl. Acad. Sci. U. S. A. 
107, 2253-2258(2010).
64. Kim, M. J. & Yoo, J. Y. Inhibition of hepatitis C virus replication by IFN-mediated 
ISGylation of HCV-NS5A. J. Immunol. 185,4311-4318 (2010).
65. Bleul, C. C., Wu, L., Hoxie, J. A., Springer, T. A. & Mackay, C. R. The HIV 
coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T 
lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 94, 1925-1930 (1997).
66. Strebel, K. Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. AIDS 17 
Suppl 4, S25-34 (2003).
67. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the 
HIV envelope glycoprotein. Cell 89, 263-273 (1997).
68. Erickson-Viitanen, S. et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: 
sequential cleavage by the viral protease. AIDS Res. Hum. Retroviruses 5, 577-591 
(1989).
69. Lillehoj, E. P. et al. Purification and structural characterization of the putative gag-pol 
protease of human immunodeficiency virus. J. Virol. 62, 3053-3058 (1988).
- 9 4 -
70. Freed, E. O., Myers, D. J. & Risser, R. Characterization of the fusion domain of the 
human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc. Natl. Acad. Sci. 
U. S. A. 87, 4650-4654 (1990).
71. Auewarakul, P., Wacharapomin, P., Srichatrapimuk, S., Chutipongtanate, S. & 
Puthavathana, P. Uncoating of HIV-1 requires cellular activation. Virology 337, 93-101
(2005).
72. Briones, M. S., Dobard, C. W. & Chow, S. A. Role of human immunodeficiency 
virus type 1 integrase in uncoating of the viral core. J. Virol. 84, 5181-5190 (2010).
73. Bachis, A., Cruz, M. I. & Mocchetti, I. M-tropic HIV envelope protein gpl20 exhibits 
a different neuropathological profile than T-tropic gpl20 in rat striatum. Eur. J. Neurosci. 
32, 570-578 (2010).
74. Cartier, C. et al. Active cAMP-dependent protein kinase incorporated within highly 
purified HIV-1 particles is required for viral infectivity and interacts with viral capsid 
protein. J. Biol. Chem. 278, 35211-35219 (2003).
75. Wacharapomin, P., Lauhakirti, D. & Auewarakul, P. The effect of capsid mutations 
on HIV-1 uncoating. Virology 358, 48-54 (2007).
76. Lanchy, J. M. et al. Dynamics of the HIV-1 reverse transcription complex during 
initiation of DNA synthesis. J. Biol. Chem. 275, 12306-12312 (2000).
77. Whitcomb, J. M. & Hughes, S. H. Retroviral reverse transcription and integration: 
progress and problems. Annu. Rev. Cell Biol. 8, 275-306 (1992).
78. Abbondanzieri, E. A. et al. Dynamic binding orientations direct activity of HIV 
reverse transcriptase. Nature 453, 184-189 (2008).
79. Sarafianos, S. G. et al. Crystal structure of HIV-1 reverse transcriptase in complex 
with a polypurine tract RNA:DNA. EM BO J. 20, 1449-1461 (2001).
80. Popov, S. et al. Viral protein R regulates nuclear import of the HIV-1 pre-integration 
complex. EMBO J. 17, 909-917 (1998).
81. Goldgur, Y. et al. Three new structures of the core domain of HIV-1 integrase: an 
active site that binds magnesium. Proc. Natl. Acad. Sci. U. S. A. 95, 9150-9154 (1998).
82. Maignan, S., Guilloteau, J. P., Zhou-Liu, Q., Clement-Mella, C. & Mikol, V. Crystal 
structures of the catalytic domain of HIV-1 integrase free and complexed with its metal 
cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 
282, 359-368(1998).
- 9 5 -
83. Cai, M. et al. Solution structure of the N-terminal zinc binding domain of HIV-1 
integrase. Nat. Struct. Biol. 4, 567-577 (1997).
84. Lodi, P. J .e t al. Solution structure of the DNA binding domain of HIV-1 integrase. 
Biochemistry 34, 9826-9833 (1995).
85. Wang, J. Y„ Ling, H., Yang, W. & Craigie, R. Structure of a two-domain fragment of 
HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20, 
7333-7343 (2001).
86. Chen, J. C. et al. Crystal structure of the HIV-1 integrase catalytic core and C- 
terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U. S. A. 97, 
8233-8238 (2000).
87. Guiot, E. et al. Relationship between the oligomeric status of HIV-1 integrase on 
DNA and enzymatic activity. J. Biol. Chem. 281, 22707-22719 (2006).
88. Faure, A. et al. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic 
Acids Res. 33, 977-986 (2005).
89. Delelis, O. et al. Insight into the integrase-DNA recognition mechanism. A specific 
DNA-binding mode revealed by an enzymatically labeled integrase. J. Biol. Chem. 283, 
27838-27849 (2008).
90. Li, M. & Craigie, R. Processing of viral DNA ends channels the HIV-1 integration 
reaction to concerted integration. J. Biol. Chem. 280, 29334-29339 (2005).
91. Gao, K., Butler, S. L. & Bushman, F. Human immunodeficiency vims type 1 
integrase: arrangement of protein domains in active cDNA complexes. EMBO J. 20, 
3565-3576 (2001).
92. Ren, G., Gao, K„ Bushman, F. D. & Yeager, M. Single-particle image reconstruction 
of a tetramer of HIV integrase bound to DNA. J. Mol. Biol. 366, 286-294 (2007).
93. Rana, T. M. & Jeang, K. T. Biochemical and functional interactions between HIV-1 
Tat protein and TAR RNA. Arch. Biochem. Biophys. 365, 175-185 (1999).
94. Dingwall, C. et al. HIV-1 tat protein stimulates transcription by binding to a U-rich 
bulge in the stem of the TAR RNA structure. EMBO J. 9,4145-4153 (1990).
95. Fujinaga, K. et al. A minimal chimera of human cyclin T1 and tat binds TAR and 
activates human immunodeficiency vims transcription in murine cells. J. Virol. 76, 
12934-12939 (2002).
-96-
96. Gold, M. 0 ., Yang, X., Herrmann, C. H. & Rice, A. P. PITALRE, the catalytic 
subunit of TAK, is required for human immunodeficiency virus Tat transactivation in 
vivo. J. Virol. 72, 4448-4453 (1998).
97. Herrmann, C. H. & Rice, A. P. Lentivirus Tat proteins specifically associate with a 
cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of 
the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69, 1612- 
1620(1995).
98. Dahmus, M. E. Reversible phosphorylation of the C-terminal domain of RNA 
polymerase II. J. Biol. Chem. 271, 19009-19012 (1996).
99. Zhu, Y. et al. Transcription elongation factor P-TEFb is required for HIV-1 tat 
transactivation in vitro. Genes Dev. 11, 2622-2632 (1997).
100. Dorr, A. et al. Transcriptional synergy between Tat and PCAF is dependent on the 
binding of acetylated Tat to the PCAF bromodomain. EMBO J. 21, 2715-2723 (2002).
101. Kieman, R. E. et al. HIV-1 tat transcriptional activity is regulated by acetylation. 
EMBO J. 18, 6106-6118 (1999).
102. Deng, L. et al. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of 
integrated HIV-1 genome and enhances binding to core histones. Virology 277, 278-295 
(2000).
103. Greger, I. H„ Demarchi, F., Giacca, M. & Proudfoot, N. J. Transcriptional 
interference perturbs the binding of Spl to the HIV-1 promoter. Nucleic Acids Res. 26, 
1294-1301 (1998).
104. Vlach, J. et al. Induction of Spl phosphorylation and NF-kappa B-independent HIV 
promoter domain activity in T lymphocytes stimulated by okadaic acid. Virology 208, 
753-761 (1995).
105. Mahanta, S. K., Scholl, T., Yang, F. C. & Strominger, J. L. Transactivation by 
OITA, the type II bare lymphocyte syndrome-associated factor, requires participation of 
multiple regions of the TATA box binding protein. Proc. Natl. Acad. Sci. U. S. A. 94, 
6324-6329 (1997).
106. Raha, T., Cheng, S. W. & Green, M. R. HIV-1 Tat stimulates transcription complex 
assembly through recruitment of TBP in the absence of TAFs. PLoS Biol. 3, e44 (2005).
107. Verrijzer, C. P., Chen, J. L„ Yokomori, K. & Tjian, R. Binding of TAFs to core 
elements directs promoter selectivity by RNA polymerase II. Cell 81, 1115-1125 (1995).
-97-
108. Feinberg, M. B„ Baltimore, D. & Frankel, A. D. The role of Tat in the human 
immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. 
Proc. Natl. Acad. Sci. U. S. A. 88, 4045-4049 (1991).
109. Sheldon, M., Ratnasabapathy, R. & Hernandez, N. Characterization of the inducer of 
short transcripts, a human immunodeficiency vims type 1 transcriptional element that 
activates the synthesis of short RNAs. Mol. Cell. Biol. 13, 1251-1263 (1993).
110. Zhou, W„ Parent, L. J„ Wills, J. W. & Resh, M. D. Identification of a membrane­
binding domain within the amino-terminal region of human immunodeficiency vims type 
1 Gag protein which interacts with acidic phospholipids. J. Virol. 68, 2556-2569 (1994).
111. Pettit, S. C„ Gulnik, S., Everitt, L. & Kaplan, A. H. The dimer interfaces of protease 
and extra-protease domains influence the activation of protease and the specificity of 
GagPol cleavage. J. Virol. 77, 366-374 (2003).
112. Pettit, S. C„ Everitt, L. E., Choudhury, S., Dunn, B. M. & Kaplan, A. H. Initial 
cleavage of the human immunodeficiency vims type 1 GagPol precursor by its activated 
protease occurs by an intramolecular mechanism. J. Virol. 78, 8477-8485 (2004).
113. Oliva, R. et al. Stmctural investigation of the HIV-1 envelope glycoprotein gpl60 
cleavage site, 2: relevance of an N-terminal helix. Chembiochem 4, 727-733 (2003).
114. Freed, E. O. HIV-1 gag proteins: diverse functions in the vims life cycle. Virology 
251, 1-15 (1998).
115. Murakami, T. & Freed, E. O. Genetic evidence for an interaction between human 
immunodeficiency vims type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J. 
Virol. 74, 3548-3554 (2000).
116. Miyauchi, K. et al. The membrane-spanning domain of gp41 plays a critical role in 
intracellular trafficking of the HIV envelope protein. Retrovirology 7, 95 (2010).
117. Franzusoff, A., Volpe, A. M., Josse, D., Pichuantes, S. & Wolf, J. R. Biochemical 
and genetic definition of the cellular protease required for HIV-1 gpl60 processing. J.
Biol. Chem. 270, 3154-3159 (1995).
118. Raja, N. U„ Vincent, M. J. & Jabbar, M. A. Analysis of endoproteolytic cleavage 
and intracellular transport of human immunodeficiency vims type 1 envelope 
glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic 
reticulum retention signal. J. Gen. Virol. 74 ( Pt 10), 2085-2097 (1993).
119. Bouloy, M. et al. Genetic evidence for an interferon-antagonistic function of rift 
valley fever virus nonstmctural protein NSs. J. Virol. 75, 1371-1377 (2001).
-98-
120. Marie, I., Durbin, J. E. & Levy, D. E. Differential viral induction of distinct 
interferon-alpha genes by positive feedback through interferon regulatory factor-7.
EMBO J. 17, 6660-6669 (1998).
121. Bowie, A. G. & Haga, I. R. The role of Toll-like receptors in the host response to 
viruses. Mol. Immunol. 42, 859-867 (2005).
122. Uematsu, S. et al. Interleukin-1 receptor-associated kinase-1 plays an essential role 
for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. 
Med. 201, 915-923 (2005).
123. Yoneyama, M. et al. The RNA helicase R1G-I has an essential function in double- 
stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730-737 (2004).
124. Kawai, T. et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I 
interferon induction. Nat. Immunol. 6, 981-988 (2005).
125. Kerkmann, M. et al. Activation with CpG-A and CpG-B oligonucleotides reveals 
two distinct regulatory pathways of type IIFN synthesis in human plasmacytoid dendritic 
cells. J. Immunol. 170, 4465-4474 (2003).
126. Novick, D., Cohen, B. & Rubinstein, M. The human interferon alpha/beta receptor: 
characterization and molecular cloning. Cell 77, 391-400 (1994).
127. Kim, S. H., Cohen, B., Novick, D. & Rubinstein, M. Mammalian type I interferon 
receptors consists of two subunits: IFNaRl and IFNaR2. Gene 196, 279-286 (1997).
128. Kisseleva, T., Bhattacharya, S., Braunstein, J. & Schindler, C. W. Signaling through 
the JAK/STAT pathway, recent advances and future challenges. Gene 285, 1-24 (2002).
129. Horvath, C. M. The Jak-STAT pathway stimulated by interferon alpha or interferon 
beta. Sci. STKE 2004, trlO (2004).
130. Goh, W. C., Manel, N. & Emerman, M. The human immunodeficiency virus Vpr 
protein binds Cdc25C: implications for G2 arrest. Virology 318, 337-349 (2004).
131. van Deursen, J., Boer, J., Kasper, L. & Grosveld, G. G2 arrest and impaired 
nucleocytoplasmic transport in mouse embryos lacking the proto-oncogene CAN/Nup214. 
EMBO J. 15, 5574-5583 (1996).
132. Wong, J. J., Pung, Y. F„ Sze, N. S. & Chin, K. C. HERC5 is an IFN-induced HECT- 
type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. 
Proc. Natl. Acad. Sci. U. S. A. 103, 10735-10740 (2006).
133. Ren, M„ Coutavas, E„ D'Eustachio, P. & Rush, M. G. Effects of mutant Ran/TC4 
proteins on cell cycle progression. Mol. Cell. Biol. 14, 4216-4224 (1994).
-99-
134. Bischoff, F. R., Krebber, H., Smirnova, E., Dong, W. & Ponstingl, H. Co-activation 
of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBPl. 
EMBO J. 14, 705-715 (1995).
135. Hetzer, M., Bilbao-Cortes, D., Walther, T. C., Gruss, O. J. & Mattaj, I. W. GTP 
hydrolysis by Ran is required for nuclear envelope assembly. Mol. Cell 5, 1013-1024 
(2000).
136. Kalab, P., Pu, R. T. & Dasso, M. The ran GTPase regulates mitotic spindle assembly. 
Curr. Biol. 9, 481-484 (1999).
137. Azuma, Y. et al. Conserved histidine residues of RCC1 are essential for nucleotide 
exchange on Ran. J. Biochem. 120, 82-91 (1996).
138. Izaurralde, E., Kutay, U., von Kobbe, C„ Mattaj, I. W. & Gorlich, D. The 
asymmetric distribution of the constituents of the Ran system is essential for transport 
into and out of the nucleus. EMBO J. 16, 6535-6547 (1997).
139. Zou, W., Wang, J. & Zhang, D. E. Negative regulation of ISG15 E3 ligase EFP 
through its autoISGylation. Biochem. Biophys. Res. Commun. 354, 321-327 (2007).
140. Watts, J. M. et al. Architecture and secondary structure of an entire HIV-1 RNA 
genome. Nature 460, 711-716 (2009).
141. Meyer, B. E. & Malim, M. H. The HIV-1 Rev trans-activator shuttles between the 
nucleus and the cytoplasm. Genes Dev. 8, 1538-1547 (1994).
142. Malim, M. H., Hauber, J., Le, S. Y., Maizel, J. V. & Cullen, B. R. The HIV-1 rev 
trans-activator acts through a structured target sequence to activate nuclear export of 
unspliced viral mRNA. Nature 338, 254-257 (1989).
143. Truant, R. & Cullen, B. R. The arginine-rich domains present in human 
immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent 
nuclear localization signals. Mol. Cell. Biol. 19, 1210-1217 (1999).
144. Henderson, B. R. & Percipalle, P. Interactions between HIV Rev and nuclear import 
and export factors: the Rev nuclear localisation signal mediates specific binding to human 
importin-beta. J. Mol. Biol. 274, 693-707 (1997).
145. Fankhauser, C., Izaurralde, E., Adachi, Y., Wingfield, P. & Laemmli, U. K. Specific 
complex of human immunodeficiency virus type 1 rev and nucleolar B23 proteins: 
dissociation by the Rev response element. Mol. Cell. Biol. 11, 2567-2575 (1991).
146. Wen, W., Meinkoth, J. L., Tsien, R. Y. & Taylor, S. S. Identification of a signal for 
rapid export of proteins from the nucleus. Cell 8 2 ,463-473 (1995).
-100-
147. Neville, M., Stutz, F„ Lee, L., Davis, L. I. & Rosbash, M. The importin-beta family 
member Crmlp bridges the interaction between Rev and the nuclear pore complex during 
nuclear export. Curr. Biol. 7, 767-775 (1997).
148. Fomerod, M„ Ohno, M., Yoshida, M. & Mattaj, I. W. CRM1 is an export receptor 
for leucine-rich nuclear export signals. Cell 90, 1051-1060 (1997).
149. Stade, K„ Ford, C. S., Guthrie, C. & Weis, K. Exportin 1 (Crmlp) is an essential 
nuclear export factor. Cell 90, 1041-1050 (1997).
150. Bischoff, F. R. & Gorlich, D. RanBPl is crucial for the release of RanGTP from 
importin beta-related nuclear transport factors. FEBS Lett. 419, 249-254 (1997).
151. Chamond, N., Locker, N. & Sargueil, B. The different pathways of HIV genomic 
RNA translation. Biochem. Soc. Trans. 38, 1548-1552 (2010).
152. Nicholson, M. G., Rue, S. M., Clements, J. E. & Barber, S. A. An internal ribosome 
entry site promotes translation of a novel SIV Pr55(Gag) isoform. Virology 349, 325-334
(2006).
153. Miele, G. & Lever, A. M. Expression of mutant and wild-type gag proteins for gene 
therapy in HIV-1 infection. Gene Ther. 3, 357-361 (1996).
154. Ricci, E. P., Soto Rifo, R., Herbreteau, C. H., Decimo, D. & Ohlmann, T. Lentiviral 
RNAs can use different mechanisms for translation initiation. Biochem. Soc. Trans. 36, 
690-693 (2008).
155. Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in 
eukaryotes: mechanisms and biological targets. Cell 136, 731-745 (2009).
156. Balvay, L., Lopez Lastra, M., Sargueil, B., Darlix, J. L. & Ohlmann, T. Translational 
control of retroviruses. Nat. Rev. Microbiol. 5, 128-140 (2007).
157. Kieft, J. S. Viral IRES RNA structures and ribosome interactions. Trends Biochem. 
Sci. 33, 274-283 (2008).
158. Pfingsten, J. S. & Kieft, J. S. RNA structure-based ribosome recruitment: lessons 
from the Dicistroviridae intergenic region IRESes. RNA 14, 1255-1263 (2008).
159. Scarlata, S. & Carter, C. Role of HIV-1 Gag domains in viral assembly. Biochim. 
Biophys. Acta 1614, 62-72 (2003).
160. Dalton, A. K., Ako-Adjei, D., Murray, P. S., Murray, D. & Vogt, V. M. Electrostatic 
interactions drive membrane association of the human immunodeficiency vims type 1 
Gag MA domain. J. Virol. 81, 6434-6445 (2007).
-101-
161. Derdowski, A., Ding, L. & Spearman, P. A novel fluorescence resonance energy 
transfer assay demonstrates that the human immunodeficiency virus type 1 Pr55Gag I 
domain mediates Gag-Gag interactions. J. Virol. 78, 1230-1242 (2004).
162. Demirov, D. G., Ono, A., Orenstein, J. M. & Freed, E. O. Overexpression of the N- 
terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. 
Proc. Natl. Acad. Sci. U. S. A. 99, 955-960 (2002).
163. Carpick, B. W. et al. Characterization of the solution complex between the 
interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans­
activating region RNA. J. Biol. Chem. 272, 9510-9516 (1997).
164. Dey, M. et al. Mechanistic link between PKR dimerization, autophosphorylation, 
and eIF2alpha substrate recognition. Cell 122, 901-913 (2005).
165. Rojas, M., Arias, C. F. & Lopez, S. Protein kinase R is responsible for the 
phosphorylation of eIF2alpha in rotavirus infection. J. Virol. 84, 10457-10466 (2010).
166. Maitra, R. K. & Silverman, R. H. Regulation of human immunodeficiency virus 
replication by 2',5'-oligoadenylate-dependent RNase L. J. Virol. 72, 1146-1152 (1998).
167. Marie, I., Svab, J., Robert, N., Galabru, J. & Hovanessian, A. G. Differential 
expression and distinct structure of 69- and 100-kDa forms of 2-5A synthetase in human 
cells treated with interferon. J. Biol. Chem. 2 6 5 ,18601-18607 (1990).
168. Maitra, R. K. et al. HIV-1 TAR RNA has an intrinsic ability to activate interferon- 
inducible enzymes. Virology 204, 823-827 (1994).
169. Yap, M. W„ Nisole, S. & Stoye, J. P. A single amino acid change in the SPRY 
domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol. 15, 73-78 (2005).
170. Kajaste-Rudnitski, A. et al. TRIM22 inhibits HIV-1 transcription independently of 
its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat 
elements. J. Virol. 85, 5183-5196 (2011).
171. Barr, S. D„ Smiley, J. R. & Bushman, F. D. The interferon response inhibits HIV 
particle production by induction of TREM22. PLoS Pathog. 4, el000007 (2008).
172. Ritchie, K. J. & Zhang, D. E. ISG15: the immunological kin of ubiquitin. Semin. 
Cell Dev. Biol. 15, 237-246 (2004).
173. Okumura, A., Lu, G., Pitha-Rowe, I. & Pitha, P. M. Innate antiviral response targets 
HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U. 
S. A. 103, 1440-1445 (2006).
-102-
174. Pincetic, A., Kuang, Z., Seo, E. J. & Leis, J. The interferon-induced gene ISG15 
blocks retrovirus release from cells late in the budding process. J. Virol. 84,4725-4736 
(2010).
175. Kerscher, O., Felberbaum, R. & Hochstrasser, M. Modification of proteins by 
ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22, 159-180 (2006).
176. Harty, R. N., Pitha, P. M. & Okumura, A. Antiviral activity of innate immune 
protein ISG15. J. Innate Immun. 1, 397-404 (2009).
177. Shi, H. X. et al. Positive regulation of interferon regulatory factor 3 activation by 
Herc5 via ISG15 modification. Mol. Cell. Biol. 30, 2424-2436 (2010).
178. Ono, A., Ablan, S. D., Lockett, S. J., Nagashima, K. & Freed, E. O. 
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma 
membrane. Proc. Natl. Acad. Sci. U. S. A. 101, 14889-14894 (2004).
179. Halwani, R., Khorchid, A., Cen, S. & Kleiman, L. Rapid localization of Gag/GagPol 
complexes to detergent-resistant membrane during the assembly of human 
immunodeficiency virus type 1. J. Virol. 77, 3973-3984 (2003).
180. Jenkins, Y. et al. Biochemical analyses of the interactions between human 
immunodeficiency virus type 1 Vpr and p6(Gag). J. Virol. 75, 10537-10542 (2001).
181. Selig, L. et al. Interaction with the p6 domain of the gag precursor mediates 
incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J. Virol. 73, 
592-600 (1999).
182. Greatorex, J., Gallego, J., Varani, G. & Lever, A. Structure and stability of wild-type 
and mutant RNA internal loops from the SL-1 domain of the HIV-1 packaging signal. J. 
Mol. Biol. 322, 543-557 (2002).
183. Amarasinghe, G. K. et al. NMR structure of the HIV-1 nucleocapsid protein bound 
to stem-loop SL2 of the psi-RNA packaging signal. Implications for genome recognition. 
J. Mol. Biol. 301, 491-511 (2000).
184. Paoletti, A. C., Shubsda, M. F., Hudson, B. S. & Borer, P. N. Affinities of the 
nucleocapsid protein for variants of SL3 RNA in HIV-1. Biochemistry 41, 15423-15428 
(2002).
185. Yuan, Y., Kerwood, D. J., Paoletti, A. C., Shubsda, M. F. & Borer, P. N. Stem of 
SL1 RNA in HIV-1: structure and nucleocapsid protein binding for a 1 x 3 internal loop. 
Biochemistry 42, 5259-5269 (2003).
186. Kerwood, D. J., Cavaluzzi, M. J. & Borer, P. N. Structure of SL4 RNA from the 
HIV-1 packaging signal. Biochemistry 40, 14518-14529 (2001).
-103-
187. Wan, M. & Loh, B. N. Expression and purification of active form of HIV-1 protease 
from E.coli. Biochem. Mol. Biol. Int. 35, 899-912 (1995).
188. Pettit, S. C., Lindquist, J. N., Kaplan, A. H. & Swanstrom, R. Processing sites in the 
human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the 
viral protease at different rates. Retrovirology 2 ,66 (2005).
189. Darke, P. L. et al. HIV-1 protease specificity of peptide cleavage is sufficient for 
processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156, 297-303 
(1988).
190. Stuchell, M. D. et al. The human endosomal sorting complex required for transport 
(ESCRT-I) and its role in HIV-1 budding. J. Biol. Chem. 279, 36059-36071 (2004).
191. von Schwedler, U. K. et al. The protein network of HIV budding. Cell 114, 701-713 
(2003).
192. Dussupt, V. et al. The nucleocapsid region of HIV-1 Gag cooperates with the PTAP 
and LYPXnL late domains to recruit the cellular machinery necessary for viral budding. 
PLoSPathog. 5, e l000339 (2009).
193. Scott, A. et al. Structural and mechanistic studies of VPS4 proteins. EMBO J. 24, 
3658-3669 (2005).
194. Shim, S., Merrill, S. A. & Hanson, P. I. Novel interactions of ESCRT-III with LIP5 
and VPS4 and their implications for ESCRT-III disassembly. Mol. Biol. Cell 19, 2661- 
2672 (2008).
195. Nakasato, N. et al. A ubiquitin E3 ligase Efp is up-regulated by interferons and 
conjugated with ISG15. Biochem. Biophys. Res. Commun. 351, 540-546 (2006).
196. Takeuchi, T., Inoue, S. & Yokosawa, H. Identification and Herc5-mediated 
ISGylation of novel target proteins. Biochem. Biophys. Res. Commun. 348, 473-477 
(2006).
197. Ji, Y. et al. The ancestral gene for transcribed, low-copy repeats in the Prader- 
Willi/Angelman region encodes a large protein implicated in protein trafficking, which is 
deficient in mice with neuromuscular and spermiogenic abnormalities. Hum. Mol. Genet. 
8,533-542(1999).
198. Hochrainer, K. et al. The human HERC family of ubiquitin ligases: novel members, 
genomic organization, expression profiling, and evolutionary aspects. Genomics 85, 153- 
164(2005).
199. Renault, L. et al. The 1.7 A crystal structure of the regulator of chromosome 
condensation (RCC1) reveals a seven-bladed propeller. Nature 392, 97-101 (1998).
-104-
200. Renault, L., Kuhlmann, J., Henkel, A. & Wittinghofer, A. Structural basis for 
guanine nucleotide exchange on Ran by the regulator of chromosome condensation 
(RCC1). Cell 105, 245-255 (2001).
201. Ohtsubo, M., Okazaki, H. & Nishimoto, T. The RCC1 protein, a regulator for the 
onset of chromosome condensation locates in the nucleus and binds to DNA. J. Cell Biol. 
109 ,1389-1397(1989).
202. Bischoff, F. R. & Ponstingl, H. Mitotic regulator protein RCC1 is complexed with a 
nuclear ras-related polypeptide. Proc. Natl. Acad. Sci. U. S. A. 88, 10830-10834 (1991).
203. Bischoff, F. R. & Ponstingl, H. Catalysis of guanine nucleotide exchange on Ran by 
the mitotic regulator RCC1. Nature 354, 80-82 (1991).
204. Quimby, B. B. & Dasso, M. The small GTPase Ran: interpreting the signs. Curr. 
Opin. Cell Biol. 15, 338-344 (2003).
205. Rosa, J. L„ Casaroli-Marano, R. P., Buckler, A. J., Vilaro, S. & Barbacid, M. p619, 
a giant protein related to the chromosome condensation regulator RCC1, stimulates 
guanine nucleotide exchange on ARF1 and Rab proteins. EMBO J. 15, 4262-4273 (1996).
206. Garcia-Gonzalo, F. R. & Rosa, J. L. The HERC proteins: functional and 
evolutionary insights. Cell Mol. Life Sci. 62, 1826-1838 (2005).
207. Takeuchi, T., Inoue, S. & Yokosawa, H. Identification and Herc5-mediated 
ISGylation of novel target proteins. Biochem. Biophys. Res. Commun. 348, 473-477 
(2006).
208. Dastur, A., Beaudenon, S., Kelley, M., Krug, R. M. & Huibregtse, J. M. Herc5, an 
interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human 
cells. J. Biol. Chem. 281, 4334-4338 (2006).
209. Versteeg, G. A. et al. Species-specific antagonism of host ISGylation by the 
influenza B virus NS1 protein. J. Virol. 84, 5423-5430 (2010).
210. Tang, Y. et al. Herc5 attenuates influenza A vims by catalyzing ISGylation of viral 
NS1 protein. J. Immunol. 184, 5777-5790 (2010).
211. Shi, H. X. et al. Positive regulation of interferon regulatory factor 3 activation by 
Herc5 via ISG15 modification. Mol. Cell. Biol. 30, 2424-2436 (2010).
212. Burkhard, P., Stetefeld, J. & Strelkov, S. V. Coiled coils: a highly versatile protein 
folding motif. Trends Cell Biol. 11, 82-88 (2001).
-105-
213. Chan, D. C., Chutkowski, C. T. & Kim, P. S. Evidence that a prominent cavity in the 
coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U. S. A. 
95, 15613-15617(1998).
214. Zou, W„ Wang, J. & Zhang, D. E. Negative regulation of ISG15 E3 ligase EFP 
through its autoISGylation. Biochem. Biophys. Res. Commun. 354, 321-327 (2007).
215. Mitsui, K. et al. A novel human gene encoding HECT domain and RCCl-like 
repeats interacts with cyclins and is potentially regulated by the tumor suppressor 
proteins. Biochem. Biophys. Res. Commun. 266, 115-122 (1999).
216. Zhao, C., Hsiang, T. Y., Kuo, R. L. & Krug, R. M. ISG15 conjugation system 
targets the viral NS 1 protein in influenza A virus-infected cells. Proc. Natl. Acad. Sci. U. 
S. A. 107, 2253-2258 (2010).
217. Sawyer, S. L., Emerman, M. & Malik, H. S. Discordant evolution of the adjacent 
antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog. 3, e l97 (2007).
218. Zhang, D. & Zhang, D. E. Interferon-stimulated gene 15 and the protein ISGylation 
system. J. Interferon Cytokine Res. 31, 119-130 (2011).
219. Jimenez-Sousa, M. A. et al. Gene expression profiling in the first twelve weeks of 
treatment in chronic hepatitis C patients. Enferm. Infecc. Microbiol. Clin. (2011).
220. Azuma, Y., Renault, L., Garcia-Ranea, J. A., Valencia, A., Nishimoto, T., 
Wittinghofer, A. Model of the Ran-RCCl interaction using biochemical and docking 
experiments. JMB. 289,1119-1130 (2009).
221. Narasimhan, J., Wang, M., Fu, Z., Klein, J. M., Haas, A. L., Kim, J. P. Crystal 
structure of the Interferon-induced ubiquitin-like protein ISG15. JBC. 280,27356-27365 
(2005).
222. Garcia-Gonzalo, F. R., Rosa, J. L. The Here proteins: functional and evolutionary 
insights. Cell. Mol. Life Sci. 62, 1826-1838 (2005).
223. Nethe, M., Hordijk, P. L. The role of ubiquitinylation and degradation in RhoTPase 
signaling. Journal o f Cell Science. 123,4011-4018 (2010).
224. Hughes, M., Zhang, C., Avis, J. M., Hutchinson, C. J., Clarke, P. R. The role of the 
Ran GTPase in nuclear assembly and DNA replication: characterization of the effects of 
Ran mutants. Journal o f cell Science. I l l ,  3017-3026 (1998).
-106-
